Patent application title: GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHOD OF MAKING AND USING THEREOF
Inventors:
Yi Zhu (Chengdu, CN)
Ole Olsen (Everett, WA, US)
Ole Olsen (Everett, WA, US)
Dong Xia (Redmond, WA, US)
David Jellyman (Duvall, WA, US)
Katrina Bykova (Seattle, WA, US)
Anne-Marie K. Rousseau (Seattle, WA, US)
Bill Brady (Bothell, WA, US)
Blair Renshaw (Renton, WA, US)
Brian Kovacevich (Snohomish, WA, US)
Brian Kovacevich (Snohomish, WA, US)
Yu Liang (Redmond, WA, US)
Camilla Wang (Sammamish, WA, US)
Zeren Gao (Redmond, WA, US)
IPC8 Class: AC07K1628FI
USPC Class:
Class name:
Publication date: 2022-01-06
Patent application number: 20220002425
Abstract:
The application provides guidance and navigation control (GNC) proteins.
In one embodiment, the GNC protein Comprises a T-cell binding moiety and
a cancer-targeting moiety, wherein the T-cell binding moiety has a
binding specificity to a T-cell receptor comprising CD3, CD28, PDL1, PD1,
OX40, 4-1BB, GITR, TIGIT, TIM-3, LAG-3, CTLA4, CD40, VISTA, ICOS, BTLA,
Light, NKp30, CD28H, CD27, CD226, CD96, CD112R, A2AR, CD160, CD244,
CECAM1, CD200R, TNFRSF25 (DR3), or a combination thereof, and wherein the
cancer targeting moiety has a binding specificity to a cancer cell
receptor.Claims:
1. A guidance and navigation control (GNC) protein, comprising a
cytotoxic cell binding moiety and a cancer-targeting moiety, wherein the
cytotoxic cell binding moiety has a binding specificity to a T-cell
receptor, a NK cell receptor, a macrophage receptor, a dendritic cell
receptor, or a combination thereof, and wherein the cancer targeting
moiety has a binding specificity to a cancer cell receptor.
2. The GNC protein of claim 1, wherein the T-cell receptor comprises CD3, CD28, PDL1, PD1, OX40, 4-1BB, GITR, TIGIT, TIM-3, LAG-3, CTLA4, CD40L, VISTA, ICOS, BTLA, Light, CD30, NKp30, CD28H, CD27, CD226, CD96, CD112R, A2AR, CD160, CD244, CECAM1, CD200R, TNFRSF25 (DR3), or a combination thereof.
3. The GNC protein of claim 1, wherein the NK cell receptor comprises CD16, NKG2D, KIR2DS1, KIR2DS2, KIR2DS4, KIR3DS1, NKG2C, NKG2E, NKG2H, NKp30a, NKp30b, NKp46, NKp80, DNAM-1, CD96, CD160, 4-1BB, GITR, CD27, OX-40, CRTAM, KIR2DL1, KIR2DL2, KIR2DL3, KIR3DL1, KIR3DL2, KIR3DL3, NKG2A, NKp30c, TIGIT, SIGLEC7, SIGLEC9, LILR, LAIR-1, KLRG1, PD-1, CTLA-4, or CD161.
4. The GNC protein of claim 1, wherein the macrophage receptor comprises TLR2, TLR4, CD16, CD64, CD40, CD80, CD86, TREM-1, TREM-2, ILT-1, ILT-6a, ILT-7, ILT-8, EMR2, Dectin-1, CD69, CD32b, SIRP.alpha., LAIR-1, VISTA, TIM-3, CD200R, CD300a, CD300f, SIGLEC1, SIGLEC3, SIGLEC5, SIGLEC7, SIGLEC9, ILT-2, ILT-3, ILT-4, ILT-5, LILRB3, LILRB4, DCIR, CSF-1R, LOX-1, CCR2, FR.beta., CD163, CR3, DC-SIGN, CD206, SR-A, CD36, MARCO.
5. The GNC protein of claim 1, wherein the dendritic cell receptor comprises TLR, CD16, CD64, CD40, CD80, CD86, HVEM, CD70, VISTA, TIM-3, LAG-3, BTLA, CSF-1R, LOX-1, CCR7, DC-SIGN, GM-CSF-R, IL-4R, IL-10R, CD36, CD206, DCIR, RIG-1, CLEC9A, CXCR4.
6. The GNC protein of claim 1, wherein the cancer receptor is a receptor on a lung cancer cell, a liver cancer cell, a breast cancer cell, a colorectal cancer cell, an anal cancer cell, a pancreatic cancer cell, a gallbladder cancer cell, a bile duct cancer cell, a head and neck cancer cell, a nasopharyngeal cancer cell, a skin cancer cell, a melanoma cell, an ovarian cancer cell, a prostate cancer cell, a urethral cancer cell, a lung cancer cell, a non-small lung cell cancer cell, a small cell lung cancer cell, a brain tumour cell, a glioma cell, a neuroblastoma cell, an esophageal cancer cell, a gastric cancer cell, a liver cancer cell, a kidney cancer cell, a bladder cancer cell, a cervical cancer cell, an endometrial cancer cell, a thyroid cancer cell, an eye cancer cell, a sarcoma cell, a bone cancer cell, a leukemia cell, a myeloma cell, a lymphoma cell, or a combination thereof.
7. The GNC protein of claim 1, wherein the cancer cell receptor comprises BCMA, CD19, CD20, CD33, CD123, CD22, CD30, ROR1, CEA, HER2, EGFR, EGFRvIII, LMP1, LMP2A, Mesothelin, PSMA, EpCAM, glypican-3, gpA33, GD2, TROP2, or a combination thereof.
8. The GNC protein of claim 1, wherein the GNC protein is capable of activating a T-cell by binding the cytotoxic cell binding moiety to the T-cell receptor.
9. The GNC protein of claim 1, comprising a bi-specific antibody or antibody monomer, a tri-specific antibody or antibody monomer, a tetra-specific antibody or antibody monomer, or a combination thereof.
10. The GNC protein of claim 1, comprising an amino acid having a percentage homology to SEQ ID NO. 49-52, wherein the percentage homology is not less than 98%.
11. The GNC protein of claim 1, comprising a first moiety, a second moiety and a linker moiety, wherein the first moiety comprises the cytotoxic cell binding moiety, wherein a second moiety comprises the cancer-targeting moiety, and wherein the first molecule and the second molecule are bound together through the linker moiety.
12. The GNC protein of claim 11, wherein the first or the second moiety comprises an antibody or a fragment thereof, a soluble receptor or a combination thereof.
13. The GNC protein of claim 11, wherein the first moiety and the first moiety are joined through a linker moiety to provide the GNC protein.
14. The GNC protein of claim 11, wherein the linker moiety covalently links the first and the second moieties to provide the GNC protein.
15. The GNC protein of claim 11, wherein the linker moiety comprises a pair of complimentary molecules or a stable protein-protein interaction.
16. The GNC protein of claim 11, wherein the pair of complimentary molecules comprises complementary strands of DNA or RNA.
17. The GNC protein of claim 11, wherein the stable protein-protein interaction comprises biotin-avidin interaction.
18. The GNC protein of claim 11, wherein the first moiety and the second moiety have binding specificities toward each other, wherein the linker moiety is the bonding affinity interaction between the first and the second moiety, and wherein the first and the second moiety are bond together to provide the GNC protein through non-covalent bonding interaction.
19. A therapeutic complex, comprising the GNC protein of claim 1 and a cytotoxic cell, wherein the cytotoxic cell comprise a T cell, a NK cell, a macrophage, a dendritic cell, or a combination thereof.
20. A therapeutic complex, comprising the GNC protein of claim 1 and a cancer cell.
21. A therapeutic complex, comprising the GNC protein of claim 1, a T-cell bound to the T-cell binding moiety and a cancer cell bound to the caner-targeting moiety.
22. A pharmaceutical composition, comprising the therapeutic complex of claim 19 and a pharmaceutically acceptable carrier.
Description:
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 62/648,880 filed Mar. 27, 2018, U.S. Provisional Patent Application No. 62/648,888 filed Mar. 27, 2018, U.S. Provisional Patent Application No. 62/551,032 filed Aug. 28, 2017, U.S. Provisional Patent Application No. 62/524,553 filed Jun. 25, 2017, U.S. Provisional Patent Application No. 62/545,603 filed Aug. 15, 2017, U.S. Provisional Patent Application No. 62/551,035 filed Aug. 28, 2017, U.S. Provisional Patent Application No. 62/551,065 filed Aug. 28, 2017, U.S. Provisional Patent Application No. 62/524,554 filed Jun. 25, 2017, U.S. Provisional Patent Application No. 62/524,557 filed Jun. 25, 2017, and U.S. Provisional Patent Application No. 62/524,558 filed Jun. 25, 2017, the entire disclosures of which are expressly incorporated by reference herein.
TECHNICAL FIELD
[0002] The present application generally relates to the technical field of Guidance and Navigation Control (GNC) proteins with multi-specific binding activities against surface molecules on both immune cells and tumor cells, and more particularly relates to making and using GNC proteins.
BACKGROUND
[0003] Cancer cells develop various strategies to evade the immune system. One of the underlaying mechanisms for the immune escape is the reduced recognition of cancer cells by the immune system. Defective presentation of cancer specific antigens or lack of thereof results in immune tolerance and cancer progression. In the presence of effective immune recognition tumors use other mechanisms to avoid elimination by the immune system. Immunocompetent tumors create suppressive microenvironment to downregulate the immune response. Multiple players are involved in shaping the suppressive tumor microenvironment, including tumor cells, regulatory T cells, Myeloid-Derived Suppressor cells, stromal cells, and other cell types. The suppression of immune response can be executed in a cell contact-dependent format as well as in and a contact-independent manner, via secretion of immunosuppressive cytokines or elimination of essential survival factors from the local environment. Cell contact-dependent suppression relies on molecules expressed on the cell surface, e.g. Programmed Death Ligand 1 (PD-L1), T-lymphocyte-associated protein 4 (CTLA-4) and others [Dunn, et al., 2004, Immunity, 21(2): 137-48; Adachi & Tamada, 2015, Cancer Sci., 106(8): 945-50].
[0004] As the mechanisms by which tumors evade recognition by the immune system continue to be better understood new treatment modalities that target these mechanisms have recently emerged. On Mar. 25, 2011, the U. S. Food and Drug Administration (FDA) approved ipilimumab injection (Yervoy, Bristol-Myers Squibb) for the treatment of unresectable or metastatic melanoma. Yervoy binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) expressed on activated T cells and blocks the interaction of CTLA-4 with CD80/86 on antigen-presenting cells thereby blocking the negative or inhibitory signal delivered into the T cell through CTLA-4 resulting in re-activation of the antigen-specific T cell leading to, in many patients, eradication of the tumor. A few years later in 2014 the FDA approved Keytruda (Pembrolizumab, Merck) and Opdivo (Nivolumab, Bristol-Myers Squibb) for treatment of advanced melanoma. These monoclonal antibodies bind to PD-1 which is expressed on activated and/or exhausted T cells and block the interaction of PD-1 with PD-L1 expressed on tumors thereby eliminating the inhibitory signal through PD-1 into the T cell resulting in re-activation of the antigen-specific T cell leading to again, in many patients, eradication of the tumor. Since then additional clinical trials have been performed comparing the single monoclonal antibody Yervoy to the combination of the monoclonal antibodies Yervoy and Opdivo in the treatment of advanced melanoma which showed improvement in overall survival and progression-free survival in the patients treated with the combination of antibodies. (Hodi et al., 2016, Lancet Oncol. 17(11):1558-1568, Hellman et al., 2018, Cancer Cell 33(5): 853-861). However, as many clinical trials have shown a great benefit of treating cancer patients with monoclonal antibodies that are specific for one or more immune checkpoint molecules data has emerged that only those patients with a high mutational burden that generates a novel T cell epitope(s) which is recognized by antigen-specific T cells show a clinical response (Snyder et al., 2014, NEJM 371:2189-2199). Those patients that have a low tumor mutational load mostly do not show an objective clinical response (Snyder et al., 2014, NEJM 371:2189-2199, Hellman et al., 2018, Cancer Cell 33(5): 853-861).
[0005] In recent years other groups have developed an alternate approach that does not require the presence of neoepitope presentation by antigen-presenting cells to activate T cells. One example is the development of a bi-specific antibody where the binding domain of an antibody which is specific for a tumor associated antigen, e.g., CD19, is linked to and antibody binding domain specific for CD3 on T cells thus creating a bi-specific T cell engager or BiTe molecule. In 2014, the FDA approved a bi-specific antibody called Blinatumumab for the treatment of Precursor B-Cell Acute Lymphoblastic Leukemia. Blinatumumab links the scFv specific for CD19 expressed on leukemic cells with the scFv specific for CD3 expressed on T cells (Bejnjamin and Stein 2016, Ther Adv Hematol 7(3):142-146). However, despite an initial response rate of >50% in patients with relapsed or refractory ALL many patients are resistant to Blinatumumab therapy or relapse after successful treatment with Blinatumumab. Evidence is emerging that the resistant to Blinatumumab or who relapse after Blinatumumab treatment is attributable to the expression of immune checkpoint inhibitory molecules expressed on tumor cells, such as PD-L1 that drives an inhibitory signal through PD-1 expressed on activated T cells (Feucht et al., 2016, Oncotarget 7(47):76902-76919). In a case study of a patient who was resistant to therapy with Blinatumumab, a second round of Blinatumumab therapy was performed but with the addition of a monoclonal antibody, pembrolizumab (Keytruda, Merck), which specifically binds to PD-1 and blocks the interaction of T cell-expressed PD-1 with tumor cell expressed PD-L1, resulted in a dramatic response and reduction of tumor cells in the bone marrow from 45% to less than 5% in this one patient (Feucht et al., 2016, Oncotarget 7(47):76902-76919). These results show that combining a bi-specific BiTe molecule with one or more monoclonal antibodies can significantly increase clinical activity compared to either agent alone. Despite the promising outcome, the cost leading to the combined therapy must be high due to multiple clinical trials and the difficulty in recruiting representative populations.
[0006] Adoptive cell therapy with chimeric antigen receptor T cells (CAR-T) is another promising immunotherapy for treating cancer. The clinical success of CAR-T therapy has revealed durable complete remissions and prolonged survival of patients with CD19-positive treatment-refractory B cell malignancies (Gill & June. 2015. Immunol Rev, 263: 68-89). However, the cost and complexity associated with the manufacture of a personalized and genetically modified CAR-T immunotherapy has restricted their production and use to specialized centers for treating relatively small numbers of patients. Cytokine release syndrome (CRS), also known as cytokine storms, is the most notable adverse effect after the infusion of engineered CAR-T cells (Bonifant et al., 201, Mol Ther Oncolytics. 3: 16011). In many cases, the onset and severity of CRS seems to be specialized personal events. Current options of mitigating CRS are mainly focused on rapid response and management care because the option of controlling CRS prior to T cell infusion is limited.
[0007] While the efficacy of CAR-T therapy specific for a CD19-positive B cell malignancy is now established, the efficacy of CAR-T therapy against solid tumors has not been unequivocally demonstrated to date. Currently, many clinical trials are in progress to explore a variety of solid tumor-associated antigens (TAA) for CAR-T therapy. Inefficient T cell trafficking into the tumors, an immunosuppressive tumor micro-environment, suboptimal antigen recognition specificity, and lack of control over treatment-related adverse events are currently considered as the main obstacles in solid tumor CAR-T therapy (Li et al., 2018, J Hematol Oncol. 11(1):22-40). The option of managing the therapeutic effect, as well as any adverse effect before and after the CAR-T cell infusion, is limited.
SUMMARY
[0008] The present application provides guidance and navigation control (GNC) proteins with multi-specific antigen binding activities to the surface molecules of a T cell and a tumour cell.
[0009] In one embodiment, the guidance and navigation control (GNC) protein, comprising a cytotoxic cell binding moiety and a cancer-targeting moiety. Any cytotoxic cells may be a potential binding target by the disclosed GNC proteins. Examples of the cytotoxic cell include, without limitation, T-cell, NK cell, macrophage cell, and dendritic cell.
[0010] In one embodiment, the GNC protein includes a T-cell binding moiety. The T-cell binding moiety has a binding specificity to a T-cell receptor. Examples T-cell receptor include without limitation CD3, CD28, PDL1, PD1, OX40, 4-1BB, GITR, TIGIT, TIM-3, LAG-3, CTLA4, CD40L, VISTA, ICOS, BTLA, Light, CD30, NKp30, CD28H, CD27, CD226, CD96, CD112R, A2AR, CD160, CD244, CECAM1, CD200R, TNFRSF25 (DR3), or a combination thereof.
[0011] In one embodiment, the GNC protein includes a NK cell binding moiety. The NK cell binding moiety has a binding specificity to a NK cell receptor. Examples NK cell receptor include, without limitation, receptors for activation of NK cell such as CD16, NKG2D, KIR2DS1, KIR2DS2, KIR2DS4, KIR3DS1, NKG2C, NKG2E, NKG2H; agonist receptors such as NKp30a, NKp30b, NKp46, NKp80, DNAM-1, CD96, CD160, 4-1BB, GITR, CD27, OX-40, CRTAM; and antagonist receptors such as KIR2DL1, KIR2DL2, KIR2DL3, KIR3DL1, KIR3DL2, KIR3DL3, NKG2A, NKp30c, TIGIT, SIGLEC7, SIGLEC9, LILR, LAIR-1, KLRG1, PD-1, CTLA-4, CD161.
[0012] In one embodiment, the GNC protein includes a macrophage binding moiety. The macrophage binding moiety has a binding specificity to a macrophage receptor. Examples macrophage receptor include, without limitation, agonist receptor on macrophage such as TLR2, TLR4, CD16, CD64, CD40, CD80, CD86, TREM-1, TREM-2, ILT-1, ILT-6a, ILT-7, ILT-8, EMR2, Dectin-1, CD69; antagonist receptors such as CD32b, SIRP.alpha., LAIR-1, VISTA, TIM-3, CD200R, CD300a, CD300f, SIGLEC1, SIGLEC3, SIGLEC5, SIGLEC7, SIGLEC9, ILT-2, ILT-3, ILT-4, ILT-5, LILRB3, LILRB4, DCIR; and other surface receptors such as CSF-1R, LOX-1, CCR2, FR.beta., CD163, CR3, DC-SIGN, CD206, SR-A, CD36, MARCO.
[0013] In one embodiment, the GNC protein includes a dendritic cell binding moiety. The dendritic cell binding moiety has a binding specificity to a dendritic cell receptor. Examples dendritic cell receptor include, without limitation, agonist receptors on dendritic cell such as TLR, CD16, CD64, CD40, CD80, CD86, HVEM, CD70; antagonist receptors such as VISTA, TIM-3, LAG-3, BTLA; and other surface receptors such as CSF-1R, LOX-1, CCR7, DC-SIGN, GM-CSF-R, IL-4R, IL-10R, CD36, CD206, DCIR, RIG-1, CLEC9A, CXCR4.
[0014] The cancer targeting moiety has a binding specificity to a cancer cell receptor. Example cancer cell receptor include without limitation BCMA, CD19, CD20, CD33, CD123, CD22, CD30, ROR1, CEA, HER2, EGFR, EGFRvIII, LMP1, LMP2A, Mesothelin, PSMA, EpCAM, glypican-3, gpA33, GD2, TROP2, or a combination thereof.
[0015] In one embodiment, GNC proteins comprise at least one T-cell binding moiety and at least one cancer cell binding moiety, wherein the T-cell binding moiety has a binding specificity to a T-cell receptor comprising CD3, CD28, PDL1, PD1, OX40, 4-1BB, GITR, TIGIT, TIM-3, LAG-3, CTLA4, CD40, VISTA, ICOS, BTLA, Light, CD30, CD27, or a combination thereof, and wherein the cancer cell binding moiety has a binding specificity to a cancer cell receptor.
[0016] In one embodiment, the cancer receptor comprises a receptor on a lung cancer cell, a liver cancer cell, a breast cancer cell, a colorectal cancer cell, an anal cancer cell, a pancreatic cancer cell, a gallbladder cancer cell, a bile duct cancer cell, a head and neck cancer cell, a nasopharyngeal cancer cell, a skin cancer cell, a melanoma cell, an ovarian cancer cell, a prostate cancer cell, a urethral cancer cell, a lung cancer cell, a non-small lung cell cancer cell, a small cell lung cancer cell, a brain tumour cell, a glioma cell, a neuroblastoma cell, an esophageal cancer cell, a gastric cancer cell, a liver cancer cell, a kidney cancer cell, a bladder cancer cell, a cervical cancer cell, an endometrial cancer cell, a thyroid cancer cell, an eye cancer cell, a sarcoma cell, a bone cancer cell, a leukemia cell, a myeloma cell, a lymphoma cell, or a combination thereof.
[0017] In one embodiment, the GNC protein is capable of activating a T-cell by binding the T-cell binding moiety to a T-cell receptor on the T-cell. In one embodiment, the GNC protein comprises a bi-specific antibody or antibody monomer, a tri-specific antibody or antibody monomer, a tetra-specific antibody or antibody monomer, an antigen-binding fragment thereof, or a combination thereof. In one embodiment, the GNC protein comprises an amino acid sequence having a percentage homology to SEQ ID NO. 49-52, wherein the percentage homology is not less than 70%, 80%, 90%, 95%, 98%, or 99%.
[0018] In one embodiment, the GNC protein may have a first moiety and a second moiety. In one embodiment, the first moiety may include a T-cell binding moiety, a NK cell binding moiety, a macrophage binding moiety, or a dendritic cell binding moiety. The second moiety comprises the cancer-targeting moiety.
[0019] In one embodiment, the first moiety and the second moiety may have binding specificities toward each other. In these embodiments, the GNC proteins are formed by the binding action between the first moiety and the second moiety. The binding action is a non-covalent bonding. In one embodiment, the GNC protein includes the first moiety bound to the second moiety through a high affinity non-covalent bonding interaction. Examples of high affinity non-covalent bonding interaction include, without limitation, antibody-antigen interaction, biotin-streptavidin interaction, leucine-zipper, and any pair of proteins from a two-hybrid screening assay, non-immunoglobulin protein scaffolds (Hosse et al., 2006, Protein Sci. 15(1): 14-27), or aptamers (Likhin et al., 2013, Acta Naturae. 2013. 5(4): 34-43), or a combination thereof.
[0020] In one embodiment, the GNC protein may further include a linker moiety. In one embodiment, the first moiety and the first moiety are joined through a linker moiety to provide the GNC protein. In one embodiment, the linker moiety may covalently link the first and the second moieties together to provide the GNC protein. In one embodiment, the linker moiety may include two complimentary molecules or a stable protein-protein interaction. Examples of complimentary molecules include without limitation the complementary strands of DNA and RNA. Examples of stable protein-protein interaction include, but not limited to, biotin-avidin, leucine-zipper, and any pair of proteins from a two-hybrid screening assay.
[0021] In one embodiment, the linker moiety may include the backbone of an immunoglobulin G (IgG), where a GNC proteins may include an immunoglobulin G (IgG) moiety with two heavy chains and two light chains, and at least two scFv moieties being covalently connected to either C or N terminals of the heavy or light chains. The IgG moiety may provide stability to the scFv moiety, and a tri-specific GNC protein may have two moieties for binding the surface molecules on T cells.
[0022] In one embodiment, the first moiety comprises an antibody or a fragment thereof, a soluble receptor or a combination thereof. In one embodiment, the second moiety comprises an antibody or a fragment, a soluble receptor or a combination thereof.
[0023] The application further provides therapeutic complexes incorporating the GNC protein disclosed herein. In one embodiment, the therapeutic complex includes the GNC protein and a cytotoxic cell. The cytotoxic cell may T cell, NK cell, macrophage, dendritic cell, or a combination thereof. In one embodiment, the T cell may be autologous T cells, allo T cells, or universal donor T cells.
[0024] In one embodiment, the therapeutic complex may include the GNC protein and a cancer cell. In one embodiment, the therapeutic complex may include the GNC protein disclosed herein having a T-cell bound to the T-cell binding moiety and a cancer cell bound to the caner-targeting moiety.
[0025] The application further provides pharmaceutical compositions. In one embodiment, the pharmaceutical composition includes the therapeutic complex disclosed herein and a pharmaceutically acceptable carrier. In one embodiment, the pharmaceutical composition includes the GNC protein disclosed herein and a pharmaceutically acceptable carrier.
[0026] In a further aspect, the application provides methods for making and using the disclosed GNC proteins.
[0027] The objectives and advantages of the present application will become apparent from the following detailed description of preferred embodiments thereof in connection with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0028] The foregoing and other features of this disclosure will become more fully apparent from the following description and appended claims, taken in conjunction with the accompanying drawings.
[0029] Understanding that these drawings depict only several embodiments arranged in accordance with the disclosure and are, therefore, not to be considered limiting of its scope, the disclosure will be described with additional specificity and detail through use of the accompanying drawings, in which:
[0030] FIG. 1 shows example GNC proteins, which are are characterized by their composition of multiple antigen binding domains (AgBd) and linkers.
[0031] FIG. 2 shows an example format of a tetra-specific GNC antibody as an embodiment.
[0032] FIG. 3 shows that an example tetra-specific GNC antibody binds to both a T cell and a tumor cell through multiple AgBds.
[0033] FIG. 4 shows the example tetra-specific GNC antibodies binding to human ROR1 transfected CHO cells.
[0034] FIG. 5 shows the example tetra-specific GNC antibodies binding to human 41BB transfected CHO cells.
[0035] FIG. 6 shows the example tetra-specific GNC antibodies binding to human PD-L1 transfected CHO cells.
[0036] FIG. 7 shows the example tetra-specific GNC antibodies with the binding domain 323H7 which is specific for the Ig domain of ROR1 meditated RTCC of the B-ALL cell line Kasumi2 with PBMC as effectors.
[0037] FIG. 8 shows the example tetra-specific GNC antibodies with the binding domain 323H7 which is specific for the Ig domain of ROR1 meditated RTCC of the B-ALL cell line Kasumi2 with CD8+, CD45RO+ memory T cells as effectors.
[0038] FIG. 9 shows the example tetra-specific GNC antibodies with the binding domain 323H7 which is specific for the Ig domain of ROR1 meditated RTCC of the B-ALL cell line Kasumi2 with CD8+, CD45RA+ naive T cells as effectors.
[0039] FIG. 10 shows the example tetra-specific GNC antibodies with the binding domain 338H4 which is specific for the Frizzled domain of ROR1 meditated RTCC of the B-ALL cell line Kasumi2 with PBMC as effectors.
[0040] FIG. 12 shows the example tetra-specific GNC antibodies with the binding domain 338H4 which is specific for the Frizzled domain of ROR1 meditated RTCC of the B-ALL cell line Kasumi2 with CD8+, CD45RA+ naive T cells as effectors.
DETAILED DESCRIPTION
[0041] In the following detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the Figures, can be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are explicitly contemplated herein.
[0042] In one embodiment, the guidance navigation control (GNC) proteins are characterized by their composition of multiple antigen-specific binding domains (AgBDs) and by their ability of directing T cells (or other effector cells) to cancer cells (or other target cells) through the binding of multiple surface molecules on a T cell and a tumor cell (FIG. 1). By this definition, GNC proteins are composed of Moiety 1 for binding at least one surface molecule on a T cell and Moiety 2 for binding at least one surface antigen on a cancer cell (TABLE 1A). In a T cell therapy, the cytotoxic T cells are regulated by T cell proliferation signaling, as well as co-stimulation signaling via either agonist receptors or antagonist receptors on their surface. To regulate these signaling, as well as the interplay between a T cell and a cancer, multiple AgBDs may be necessary for Moiety 1 and Moiety 2, respectively. GNC proteins must have at least one linker to link Moiety 1 and Moiety 2. In a conceptual GNC protein, any linker molecule can be used to link two or more AgBDs together either in vitro or in vivo by using complementary linkers of DNA/RNA or protein-protein interactions, including but not limited to, that of biotin-avidin, leucine-zipper, and any two-hybrid positive protein. However, in the present application all the linkers are either an antibody backbone structure or antibody fragments, so that GNC protein and GNC antibody may have the same meaning, e.g. an example of a tetra-specific GNC antibody structure in FIG. 2. GNC proteins or antibodies are capable of directing the binding of a Tcell to a cancer cell in vivo or ex vivo, mediated by multiple AgBDs (FIG. 3). The Tcells may be derived from the same patient or different individuals, and the cancer cell may exist in vivo, in vitro, or ex vivo. The examples provided in the present application enable GNC proteins as a prime agent in a Tcell therapy, i.e. GNC-T therapy, for activating and controlling cytotoxic Tcells ex vivo, prior to adoptive transfer.
TABLE-US-00001 TABLE 1A Composition of functional moieties (Moiety 1 and Moiety 2) and antigen binding domain in example GNC proteins with T cell binding domains Moiety 1 Moiety 2 Activation of T cells Agonist receptor Antagonist receptor Tumor Antigen CD3 CD28, 41BB, OX40, PDL1, PD1, TIGIT, TIM- BCMA, CD19, CD20, GITR, CD40L, ICOS, 3, LAG-3, CTLA4, BTLA, CD33, CD123, CD22, Light, CD27, CD30 VISTA, PDL2 CD30, ROR1, CEA, HER2, EGFR, EGFRvIII, LMP1, LMP2A, Mesothelin, PSMA, EpCAM, glypican-3, gpA33, GD2, TROP2
[0043] In addition to Tcells, other cytotoxic cells may also be utilized by the GNC proteins for cancer killing or preventing purposes. TABLE 1B shows the example compositions of functional moieties (Moiety 1 and Moiety 2) and antigen binding domain in GNC proteins with NK cell binding domains. TABLE 1C shows the example compositions of functional moieties (Moiety 1 and Moiety 2) and antigen binding domain in GNC proteins with macrophage binding domains. TABLE 1D shows the example compositions of functional moieties (Moiety 1 and Moiety 2) and antigen binding domain in GNC proteins with dendritic cell binding domains.
TABLE-US-00002 TABLE 1B Moiety 1 Moiety 2 Activation of NK cell Agonist receptor Antagonist receptor Tumor Antigen CD16, NKG2D, NKp30a, NKp30b, KIR2DL1, KIR2DL2, BCMA, CD19, CD20, KIR2DS1, KIR2DS2, NKp46, NKp80, KIR2DL3, KIR3DL1, CD33, CD123, CD22, KIR2DS4, KIR3DS1, DNAM-1, CD96, KIR3DL2, KIR3DL3, CD30, ROR1, CEA, HER2, NKG2C, NKG2E, CD160, 4-1BB, GITR, NKG2A, NKp30c, TIGIT, EGFR, EGFRvIII, LMP1, NKG2H CD27, OX-40, CRTAM SIGLEC7, SIGLEC9, LILR, LMP2A, Mesothelin, LAIR-1, KLRG1, PD-1, PSMA, EpCAM, CTLA-4, CD161 glypican-3, gpA33, GD2, TROP2
TABLE-US-00003 TABLE 1C Moiety 1 Agonist receptor on Antagonist receptor on Other surface Moiety 2 macrophage macrophage receptors Tumor Antigen TLR2, TLR4, CD16, CD32b, SIRP.alpha., LAIR-1, VISTA, CSF-1R, LOX-1, BCMA, CD19, CD20, CD64, CD40, CD80, TIM-3, CD200R, CD300a, CCR2, FR.beta., CD33, CD123, CD22, CD86, TREM-1, TREM-2, CD300f, SIGLEC1, SIGLEC3, CD163, CR3, DC- CD30, ROR1, CEA, ILT-1, ILT-6a, ILT-7, ILT- SIGLEC5, SIGLEC7, SIGLEC9, SIGN, CD206, SR- HER2, EGFR, EGFRvIII, 8, EMR2, Dectin-1, ILT-2, ILT-3, ILT-4, ILT-5, A, CD36, MARCO LMP1, LMP2A, CD69 LILRB3, LILRB4, DCIR Mesothelin, PSMA, EpCAM, glypican-3, gpA33, GD2, TROP2
TABLE-US-00004 TABLE 1D Moiety 1 Antagonist receptor on Other surface Moiety 2 Agonist receptor on DC DC receptors Tumor Antigen TLR, CD16, CD64, CD40, VISTA, TIM-3, LAG-3, BTLA CSF-1R, LOX-1, BCMA, CD19, CD20, CD80, CD86, HVEM, CD70 CCR7, DC-SIGN, CD33, CD123, CD22, GM-CSF-R, IL-4R, CD30, ROR1, CEA, IL-10R, CD36, HER2, EGFR, EGFRvIII, CD206, DCIR, RIG- LMP1, LMP2A, 1, CLEC9A, CXCR4 Mesothelin, PSMA, EpCAM, glypican-3, gpA33, GD2, TROP2
[0044] The present application relates to methods of making and using recombinant GNC proteins. Multiple AgBDs can be divided into Moiety 1 and Moiety 2 due to their interface with a cytotoxic cell such as a T cell and a cancer cell, respectively (TABLE 1A). However, the rearrangement of multiple AgBDs may be random and in unequal numbers (TABLE 2). A GNC protein with two AgBDs may simultaneously bind to a surface molecule, such as CD3 on a T cell, and a tumor antigen, such as ROR1 on a tumor cell, for re-directing or guiding the T cell to the tumor cell. The addition of the third AgBD, e.g. specifically bind to 41BB, may help enhance anti-CD3-induced Tcell activation because 41BB is a co-stimulation factor and the binding stimulates its agonist activity to activated T cells. The addition of the fourth AgBD to a GNC protein, e.g. specifically bind to PD-L1 on a tumor cell, may block the inhibitory pathway of PD-L1 on tumor cells that is mediated through its binding to PD-1 on the T cells. With these basic principles, GNC proteins may be designed and constructed to acquire multiple AgBDs specifically for binding unequal numbers of Tcell antagonists and agonists, not only to re-direct activated Tcells to tumor cells but also to control their activity in vivo (TABLE 2). Therefore, the design of GNC proteins may be any multi-specific proteins.
[0045] In one embodiment, the GNC protein may be a bi-specific, tri-specific, tetra-specific, penta-specific, hexa-specific, hepta-specific, or octa-specific proteins. In one embodiment, the GNC protein may be a monoclonal antibodies. In one embodiment, the GNC protein may be a bi-specific, tri-specific, tetra-specific, penta-specific, hexa-specific, hepta-specific, or octa-specific antibody monomers. In one embodiment, the GNC protein may be a bi-specific, tri-specific, tetra-specific, penta-specific, hexa-specific, hepta-specific, or octa-specific antibodies. TABLE 3 provides some example GNC proteins and antibodies with the specificity of antibody binding domains.
TABLE-US-00005 TABLE 2 Examples of possible combinations of T cell activation, T cell agonist, T cell antagonist, and tumor antigen binding domains in a single GNC protein. T cell Tumor T cell T cell T cell T cell T cell T cell GNC protein activation antigen antagonist agonist antagonist antagonist antagonist agonist Bi-specific CD3 ROR1 Tri-specific CD3 ROR1 PD1 Tetra-specific CD3 ROR1 PD1 41BB Penta-specific CD3 ROR1 PD1 41BB LAG3 Hexa-specific CD3 ROR1 PD1 41BB LAG3 TLM3 Hepta-specific CD3 ROR1 PD1 41BB LAG3 TLM3 TIGIT Octa-specific CD3 ROR1 PD1 41BB LAG3 TLM3 TIGIT CD28
TABLE-US-00006 TABLE 3 Specificity of antibody binding domains used in GNC proteins. Antibody Name Specificity 460C3 41BB 420H5 41BB 466F6 41BB PL230C6 PD-L1 323H7 ROR1 IgD Domain 338H4 ROR1 Frizzled Domain 330F11 ROR1 Kringle Domain 324C6 ROR1 Frizzled Domain 4420 FITC 284A10 CD3 complex Epsilon chain 480C8 CD3 complex Epsilon chain
[0046] In one embodiment, the application provides methods of making and using recombinant GNC proteins. GNC proteins are composed of multi-specific antigen binding moieties characterized by two functional groups: Moiety 1 comprises multiple antigen binding domains (AgBD) whose specificities are implicated in T-cell activation, agonist co-stimulation, and/or inhibitory antagonist activity, and Moiety 2 comprises at least one cancer cell binding specificity. GNC proteins may simultaneously bind to a surface molecule, such as CD3 of a T cell, and a tumor antigen, such as ROR1 of a tumor cell, thereby re-directing or guiding the T cell to the tumor cell. An addition of the third binding domain in a GNC protein may help enhance the CD3-induced T cell activation through its direct binding of 41BB, which is a co-stimulation factor exerting agonist activity. Furthermore, an addition of the fourth binding domain in a GNC protein may bind to PD-L1 on the tumor cell to block the inhibitory pathway of PD-L1 on tumor cells that is mediated through its binding to PD-1 on the T cells. In this way, GNC proteins acquire multiple binding capacities to re-direct activated T cells to tumor cells, and multiple binding may help modulate T cell activation through modulating either agonist or antagonist activity or both. Some binding capacities may be similar to that of either the chimeric antigen receptor on a CAR-T cell or a bi-specific antibody, such as the BiTe antibody. While GNC proteins are unique, their ability of guidance and navigation control of the interaction between activated T cells and tumor cells remains to be demonstrated.
[0047] In one embodiment, an example GNC protein with 4 different binding domains is disclosed. This GNC protein is a "tetra-specific antibody" since its linkers and backbone comprises antibody fragments. Of the 4 different antigen binding domains, one specifically binds to CD3 on T cells, the second binding domain is specific against a tumor associated antigen, including but not limited to other tumor antigens, such as ROR1, CEA, HER2, EGFR, EGFRvIII, LMP1, LMP2A, Mesothelin, PSMA, EpCAM, glypican-3, gpA33, GD2, TROP2, BCMA, CD19, CD20, CD33, CD123, CD22, CD30, and the third and fourth binding domains are specific against two distinct immune checkpoint modulators, namely, PD-L1, PD-1, OX40, 4-1BB, GITR, TIGIT, TIM-3, LAG-3, CTLA4, CD40, VISTA, ICOS, BTLA, Light, HVEM, CD73, CD39, etc. Because of their definition in function and variety in composition, GNC proteins can be classified as a new class of immune-modulators for treating cancer. TABLE 4 shows the list of the example tetra-specific GNC antibodies.
TABLE-US-00007 TABLE 4 List of tetra-specific GNC antibodies. Antibody Domain 1 Humanized Domain 2 Humanized Domain 3 Humanized Domain 4 Humanized ID LH-scFv Variant Fab Variant IgG Fc LH-scFv Variant LH-scFv Variant SI-35E18 460C3 H1L1 PL230C6 H3L3 n2 323H7 H4L1 284A10 H1L1 SI-35E19 420H5 H3L3 PL230C6 H3L3 n2 323H7 H4L1 284A10 H1L1 SI-35E20 466F6 H2L5 PL230C6 H3L3 n2 323H7 H4L1 284A10 H1L1 SI-35E21 460C3 H1L1 PL230C6 H3L3 n2 338H4 H3L4 284A10 H1L1 SI-35E22 420H5 H3L3 PL230C6 H3L3 n2 338H4 H3L4 284A10 H1L1 SI-35E23 466F6 H2L5 PL230C6 H3L3 n2 338H4 H3L4 284A10 H1L1 SI-35E24 460C3 H1L1 PL230C6 H3L3 n2 330F11 H1L1 284A10 H1L1 SI-35E25 420H5 H3L3 PL230C6 H3L3 n2 330F11 H1L1 284A10 H1L1 SI-35E26 466F6 H2L5 PL230C6 H3L3 n2 330F11 H1L1 284A10 H1L1 SI-27E12 4420 ~ PL230C6 H3L3 n2 324C6 H2L1 480C8 H1L1 SI-27E15 460C3 H1L1 4420 ~ n2 324C6 H2L1 480C8 H1L1 SI-27E13 460C3 H1L1 PL230C6 H3L3 n2 4420 ~ 480C8 H1L1 SI-35E2 460C3 H1L1 PL230C6 H3L3 n2 324C6 H2L1 4420 ~
[0048] In one embodiment, GNC-mediated immunotherapy may include types of antibody therapy and cell therapy. Herein, the advantages may include, but not limited to, the inclusion of an IgG Fc domain may confer the characteristic of a longer half-life in serum compared to a bi-specific BiTe molecule; second, the inclusion of two binding domains specific for immune checkpoint modulators may inhibit the suppressive pathways and engage the co-stimulatory pathways at the same time; third, that cross-linking CD3 on Tcells with tumor associated antigens re-directs and guides Tcells to kill the tumor cells without the need of removing Tcells from the patient and genetically modifying them to be specific for the tumor cells before re-introducing them back into the patient, also known as chimeric antigen receptor Tcells (CAR-T) therapy; and fourth, that GNC protein-mediated antibody therapy or Tcell therapy does not involve genetic modification of Tcells, the latter of which may carry the risk of transforming modified Tcells to clonal expansion, i.e. T cell leukemia.
[0049] With one or more addition of the binding capacity, the advantage of GNC protein-mediated immunotherapy over conventional immunotherapies include, but not limited to, first, that inclusion of an IgG Fc domain may confer the characteristic of a longer half-life in serum compared to a bi-specific BiTe molecule; second, that inclusion of two binding domains specific for immune checkpoint modulators may inhibit the suppressive pathways and engage the co-stimulatory pathways at the same time; third, that cross-linking CD3 on Tcells with tumor associated antigens re-directs and guides T cells to kill the tumor cells without the need of removing Tcells from the patient and genetically modifying them to be specific for the tumor cells before re-introducing them back into the patient, also known as chimeric antigen receptor Tcells (CAR-T) therapy; and fourth, that GNC protein-mediated antibody therapy or Tcell therapy does not involve genetic modification of Tcells, the latter of which may carry the risk of transforming modified Tcells to clonal expansion, i.e. Tcell leukemia.
[0050] The present disclosure may be understood more readily by reference to the following detailed description of specific embodiments and examples included herein. Although the present disclosure has been described with reference to specific details of certain embodiments thereof, it is not intended that such details should be regarded as limitations upon the scope of the disclosure.
EXAMPLES
[0051] While the following examples are provided by way of illustration only and not by way of limitation. Those of skill in the art will readily recognize a variety of non-critical parameters that could be changed or modified to yield essentially the same or similar results.
Example 1: FACS Analysis of Tetra-Specific Specific Antibody Binding to Human ROR1 Transfected CHO Cells
[0052] The tetra-specific GNC antibodies listed in TABLEs 3 and 4 were tested for binding to Chinese hamster ovary cells (CHO) cells stably expressing a full-length human ROR1. Antibodies were prepared at 2.times. final concentration and titrated 1:5 across 3 wells of a 96 well plate in 50 ul of PBS/2% FBS and then 5,000 ROR1-CHO cells in 50 ul PBS/2% FBS were added. This mixture was incubated for 30 minutes on ice, washed once with 200 ul PBS/2% FBS, and then the secondary antibody PE Goat anti-Human IgG Fc at 1:1000 dilution of stock was added, and this mixture was incubated for 30 minutes on ice. Cells were washed 2.times.200 ul PBS/2% FBS, resuspended in 50 ul PBS/2% FBS and analyzed on a BD LSRFORTESSA and the binding profile is shown in FIG. 4. The tetra-specific antibodies SI-35E18, 19, and 20, with the 323H7 binding domain specific for the Ig domain of ROR1, showed higher binding than the tetra-specific GNC antibodies SI-3521, 22, and 23, with the 338H4 binding domain specific for the frizzled domain of ROR1, and the tetra-specific GNC antibodies SI-3524, 25, and 26, with the 330F11 binding domain specific for the kringle domain of ROR1, did not bind.
Example 2: FACS Analysis of Tetra-Specific GNC Antibody Binding to Human 41BB Transfected CHO Cells
[0053] The tetra-specific GNC antibodies listed in TABLEs 3 and 4 were tested for binding to Chinese hamster ovary cells (CHO) cells stably expressing a full-length human ROR1. Antibodies were prepared at 2.times. final concentration and titrated 1:5 across 3 wells of a 96 well plate in 50 ul of PBS/2% FBS and then 5,000 ROR1-CHO cells in 50 ul PBS/2% FBS were added. This mixture was incubated for 30 minutes on ice, washed once with 200 ul PBS/2% FBS, and then the secondary antibody PE Goat anti-Human IgG Fc at 1:1000 dilution of stock was added, and this mixture was incubated for 30 minutes on ice. Cells were washed 2.times.200 ul PBS/2% FBS, resuspended in 50 ul PBS/2% FBS and analyzed on a BD LSRFORTESSA and the binding profile is shown in FIG. 5. All of the tetra-specific GNC antibodies except for the control SI-27E12 contain a 41BB binding domain, 460C3, 420H5, or 466F6 and bound to 41BB expressing CHO cells with varying intensity.
Example 3: FACS Analysis of Tetra-Specific GNC Antibody Binding to Human PDL1 Transfected CHO Cells
[0054] The tetra-specific GNC antibodies listed in TABLEs 3 and 4 were tested for binding to Chinese hamster ovary cells (CHO) cells stably expressing full length human ROR1. Antibodies were prepared at 2.times. final concentration and titrated 1:5 across 3 wells of a 96 well plate in 50 ul of PBS/2% FBS and then 5,000 ROR1-CHO cells in 50 ul PBS/2% FBS were added. This mixture was incubated for 30 minutes on ice, washed once with 200 ul PBS/2% FBS, and then the secondary antibody PE Goat anti-Human IgG Fc at 1:1000 dilution of stock was added, and this mixture was incubated for 30 minutes on ice. Cells were washed 2.times.200 ul PBS/2% FBS, resuspended in 50 ul PBS/2% FBS and analyzed on a BD LSRFORTESSA and the binding profile is shown in FIG. 6. All of the tetra-specific GNC antibodies except for the control SI-27E15 contain the same PDL1 binding domain, PL230C6, and showed very similar binding intensity to PDL1 expressing CHO cells.
Example 4: Re-Directed T Cell Cytotoxicity (RTCC) Assay with Peripheral Blood Mononuclear Cells as Effectors and B-Acute Lymphoblastic Leukemia (B-ALL) Cell Line Kasumi-2 as Targets
[0055] The tetra-specific GNC antibodies listed in TABLEs 3 and 4 were tested for RTCC activity against the B-ALL cell line Kasumi 2 using human peripheral blood mononuclear cells (PBMC) as effectors. The Kasumi 2 target cells, 5.times.10.sup.6, were labeled with CFSE (Invitrogen, #C34554) at 0.5 uM in 10 ml of culture media for 20 minutes at 37.degree. C. The cells were washed 3 times with 50 ml of culture media before resuspending in 10 ml then counted again. Antibodies were prepared at 2.times. final concentration and titrated 1:3 across 10 wells of a 96 well plate in 200 ul of RPMI+10% FBS. Human PBMC were purified by standard ficoll density gradient from a "leukopak" which is an enriched leukapheresis product collected from normal human peripheral blood. In the final destination 96 well plate the target cells, PBMC, and serially titrated antibodies were combined by adding 100 ul of target cells (5,000), 50 ul of PBMC (25,000), and 100 ul of each antibody dilution to each well of the assay. The assay plate was incubated at 37.degree. C. for approximately 72 hours and then the contents of each assay well were harvested and analyzed for the number of CFSE-labeled target cells remaining. As shown on FIG. 7, the tetra-specific GNC antibodies all contain the same PDL1 binding domain PL230C6, the same ROR1 binding domain 323H7, and the same CD3 binding domain 284A10, but have one of the 41BB binding domains 460C3, 420H5, and 466F6 and showed greater RTCC activity compared to the controls except for the control SI-27E12 which does not have a 41BB binding domain but appeared to be similarly potent at the tetra-specific GNC antibodies SI-35E18, 19, and 20.
Example 5: Re-Directed T Cell Cytotoxicity (RTCC) Assay with CD8+. CD45RO+ Memory T Cells as Effectors and B-Acute Lymphoblastic Leukemia (B-ALL1 Cell Line Kasumi-2 as Targets
[0056] The tetra-specific GNC antibodies listed in TABLE 3 and 4 were tested for RTCC activity against the B-ALL cell line Kasumi 2 using human CD8+, CD45RO+ memory T cells as effectors. The Kasumi 2 target cells, 5.times.10.sup.6, were labeled with CFSE (Invitrogen, #C34554) at 0.5 uM in 10 ml of culture media for 20 minutes at 37.degree. C. The cells were washed 3 times with 50 ml of culture media before resuspending in 10 ml then counted again. Antibodies were prepared at 2.times. final concentration and titrated 1:3 across 10 wells of a 96 well plate in 200 ul of RPMI+10% FBS. Human CD8+, CD45RO+ memory T cells were enriched from PBMC from a normal donor using the EasySep.TM. Human Memory CD8+ T Cell Enrichment Kit (Stemcell Technologies, #19159) as per the manufacturers protocol. The final cell population was determined to be 98% CD8+, CD45RO+ T cells by FACS analysis. In the final destination 96 well plate the target cells, T cells, and serially titrated antibodies were combined by adding 100 ul of target cells (5,000), 50 ul of CD8+, CD45RO+ memory T cells (25,000), and 100 ul of each antibody dilution to each well of the assay. The assay plate was incubated at 37 C for approximately 72 hours and then the contents of each assay well were harvested and analyzed for the number of CFSE-labeled target cells remaining. As shown on FIG. 8, the tetra-specific antibodies all contain the same PDL1 binding domain PL230C6, the same ROR1 binding domain 323H7, and the same CD3 binding domain 284A10, but have one of the 41BB binding domains 460C3, 420H5, and 466F6 and showed greater RTCC activity compared to the controls that do not contain one of the 41BB, PDL1, ROR1, or CD3 binding domains.
Example 6: Re-Directed T Cell Cytotoxicity (RTCC) Assay with CD8+. CD45RA+ Naive T Cells as Effectors and B-Acute Lymphoblastic Leukemia (B-ALL) Cell Line Kasumi-2 as Targets
[0057] The tetra-specific-specific antibodies listed in TABLEs 3 and 4 were tested for RTCC activity against the B-ALL cell line Kasumi 2 using human CD8+, CD45RA+ memory T cells as effectors. The Kasumi 2 target cells, 5.times.10e6, were labeled with CFSE (Invitrogen, #C34554) at 0.5 uM in 10 ml of culture media for 20 minutes at 37 C. The cells were washed 3 times with 50 ml of culture media before resuspending in 10 ml then counted again. Antibodies were prepared at 2.times. final concentration and titrated 1:3 across 10 wells of a 96 well plate in 200 ul of RPMI+10% FBS. Human CD8+, CD45RA+ memory T cells were enriched from peripheral blood mononuclear cells from a normal donor using the EasySep.TM. Human Naive CD8+ T Cell Isolation Kit (Stemcell Technologies, #19258) as per the manufacturers protocol. The final cell population was determined to be 98% CD8+, CD45RA+ T cells by FACS analysis (data not shown). In the final destination 96 well plate the target cells, T cells, and serially titrated antibodies were combined by adding 100 ul of target cells (5,000), 50 ul of CD8+, CD45RO+ T cells (25,000), and 100 ul of each antibody dilution to each well of the assay. The assay plate was incubated at 37 C for approximately 72 hours and then the contents of each assay well were harvested and analyzed for the number of CFSE-labeled target cells remaining. As shown on FIG. 9, the tetra-specific antibodies all contain the same PDL1 binding domain PL230C6, the same ROR1 binding domain 323H7, and the same CD3 binding domain 284A10, but have one of the 41BB binding domains 460C3, 420H5, and 466F6 and showed greater RTCC activity compared to the controls that do not contain one of the 41BB, PDL1, ROR1, or CD3 binding domains.
Example 7: Re-Directed T Cell Cytotoxicity (RTCC) Assay with Peripheral Blood Mononuclear Cells as Effectors and B-Acute Lymphoblastic Leukemia (B-ALL) Cell Line Kasumi-2 as Targets
[0058] The tetra-specific-specific antibodies listed in TABLEs 3 and 4 were tested for RTCC activity against the B-ALL cell line Kasumi 2 using human peripheral blood mononuclear cells (PBMC) as effectors. The Kasumi 2 target cells, 5.times.10.sup.6, were labeled with CFSE (Invitrogen, #C34554) at 0.5 M in 10 ml of culture media for 20 minutes at 37.degree. C. The cells were washed 3 times with 50 ml of culture media before resuspending in 10 ml then counted again. Antibodies were prepared at 2.times. final concentration and titrated 1:3 across 10 wells of a 96 well plate in 200 l of RPMI+10% FBS. Human PBMC were purified by standard ficoll density gradient from a "leukopak" which is an enriched leukapheresis product collected from normal human peripheral blood. In the final destination 96 well plate the target cells, PBMC, and serially titrated antibodies were combined by adding 100 ul of target cells (5,000), 50 ul of PBMC (25,000), and 100 ul of each antibody dilution to each well of the assay. The assay plate was incubated at 37.degree. C. for approximately 72 hours and then the contents of each assay well were harvested and analyzed for the number of CFSE-labeled target cells remaining. As shown on FIG. 10, the tetra-specific GNC antibodies all contain the same PDL1 binding domain PL230C6, the same ROR1 binding domain 338H4, and the same CD3 binding domain 284A10, but have one of the 41BB binding domains 460C3, 420H5, and 466F6 and showed greater RTCC activity compared to the controls except for the control SI-35E36 which does not have a 41BB binding domain but appeared to be similarly potent at the tetra-specific GNC antibodies SI-35E18, 19, and 20.
Example 8: Re-Directed T Cell Cytotoxicity (RTCC) Assay with CD8+. CD45RO+ Memory T Cells as Effectors and B-Acute Lymphoblastic Leukemia (B-ALL) Cell Line Kasumi-2 as Targets
[0059] The tetra-specific GNC antibodies listed in TABLEs 3 and 4 were tested for RTCC activity against the B-ALL cell line Kasumi 2 using human CD8+, CD45RO+ memory T cells as effectors. The Kasumi 2 target cells, 5.times.10.sup.6, were labeled with CFSE (Invitrogen, #C34554) at 0.5 uM in 10 ml of culture media for 20 minutes at 37.degree. C. The cells were washed 3 times with 50 ml of culture media before resuspending in 10 ml then counted again. Antibodies were prepared at 2.times. final concentration and titrated 1:3 across 10 wells of a 96 well plate in 200 ul of RPMI+10% FBS. Human CD8+, CD45RO+ memory T cells were enriched from PBMC from a normal donor using the EasySep.TM. Human Memory CD8+ T Cell Enrichment Kit (Stemcell Technologies, #19159) as per the manufacturers protocol. The final cell population was determined to be 98% CD8+, CD45RO+ T cells by FACS analysis (data not shown). In the final destination 96 well plate the target cells, T cells, and serially titrated antibodies were combined by adding 100 l of target cells (5,000), 50 ul of CD8+, CD45RO+ memory T cells (25,000), and 100 ul of each antibody dilution to each well of the assay. The assay plate was incubated at 37.degree. C. for approximately 72 hours and then the contents of each assay well were harvested and analyzed for the number of CFSE-labeled target cells remaining. As shown on FIG. 11, the tetra-specific GNC antibodies all contain the same PDL1 binding domain PL230C6, the same ROR1 binding domain 338H4, and the same CD3 binding domain 284A10, but have one of the 41BB binding domains 460C3, 420H5, and 466F6 and showed greater RTCC activity compared to the controls that do not contain one of the 41BB, PDL1, ROR1, or CD3 binding domains.
Example 9: Re-Directed T Cell Cytotoxicity (RTCC) Assay with CD8+. CD45RA+ Naive T Cells as Effectors and B-Acute Lymphoblastic Leukemia (B-ALL) Cell Line Kasumi-2 as Targets
[0060] The tetra-specific GNC antibodies listed in TABLEs 3 and 4 were tested for RTCC activity against the B-ALL cell line Kasumi 2 using human CD8+, CD45RA+ memory T cells as effectors. The Kasumi 2 target cells, 5.times.10.sup.6, were labeled with CFSE (Invitrogen, #C34554) at 0.5 M in 10 ml of culture media for 20 minutes at 37.degree. C. The cells were washed 3 times with 50 ml of culture media before resuspending in 10 ml then counted again. Antibodies were prepared at 2.times. final concentration and titrated 1:3 across 10 wells of a 96 well plate in 200 ul of RPMI+10% FBS. Human CD8+, CD45RA+ memory T cells were enriched from PBMC from a normal donor using the EasySep.TM. Human Naive CD8+ T Cell Isolation Kit (Stemcell Technologies, #19258) as per the manufacturers protocol. The final cell population was determined to be 98% CD8+, CD45RA+ T cells by FACS analysis. In the final destination 96 well plate the target cells, T cells, and serially titrated antibodies were combined by adding 100 ul of target cells (5,000), 50 ul of CD8+, CD45RO+ T cells (25,000), and 100 l of each antibody dilution to each well of the assay. The assay plate was incubated at 37.degree. C. for approximately 72 hours and then the contents of each assay well were harvested and analyzed for the number of CFSE-labeled target cells remaining. As shown on FIG. 12, the tetra-specific GNC antibodies all contain the same PDL1 binding domain PL230C6, the same ROR1 binding domain 338H4, and the same CD3 binding domain 284A10, but have one of the 41BB binding domains 460C3, 420H5, and 466F6 but did not show greater RTCC activity compared to the controls that do not contain one of the 41BB, PDL1, ROR1, or CD3 binding domains. This is in contrast to the tetra-specific GNC antibodies described in Example 6 and shown in FIG. 6 that do show RTCC activity with CD8+, CD45RA+ naive T cells.
[0061] The term "antibody" is used in the broadest sense and specifically covers single monoclonal antibodies (including agonist and antagonist antibodies), antibody compositions with polyepitopic specificity, as well as antibody fragments (e.g., Fab, F(ab')2, and Fv), so long as they exhibit the desired biological activity. In some embodiments, the antibody may be monoclonal, polyclonal, chimeric, single chain, bispecific or bi-effective, simianized, human and humanized antibodies as well as active fragments thereof. Examples of active fragments of molecules that bind to known antigens include Fab, F(ab')2, scFv and Fv fragments, including the products of an Fab immunoglobulin expression library and epitope-binding fragments of any of the antibodies and fragments mentioned above. In some embodiments, antibody may include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e. molecules that contain a binding site that immunospecifically bind an antigen. The immunoglobulin can be of any type (IgG, IgM, IgD, IgE, IgA and IgY) or class (IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclasses of immunoglobulin molecule. In one embodiment, the antibody may be whole antibodies and any antigen-binding fragment derived from the whole antibodies. A typical antibody refers to heterotetrameric protein comprising typically of two heavy (H) chains and two light (L) chains. Each heavy chain is comprised of a heavy chain variable domain (abbreviated as VH) and a heavy chain constant domain. Each light chain is comprised of a light chain variable domain (abbreviated as VL) and a light chain constant domain. The VH and VL regions can be further subdivided into domains of hypervariable complementarity determining regions (CDR), and more conserved regions called framework regions (FR). Each variable domain (either VH or VL) is typically composed of three CDRs and four FRs, arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from amino-terminus to carboxy-terminus. Within the variable regions of the light and heavy chains there are binding regions that interacts with the antigen.
[0062] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present disclosure may be made by the hybridoma method first described by Kohler & Milstein, Nature, 256:495 (1975), or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567).
[0063] The monoclonal antibodies may include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855
[1984]).
[0064] Monoclonal antibodies can be produced using various methods including mouse hybridoma or phage display (see Siegel. Transfus. Clin. Biol. 9:15-22 (2002) for a review) or from molecular cloning of antibodies directly from primary B cells (see Tiller. New Biotechnol. 28:453-7 (2011)). In the present disclosure antibodies were created by the immunization of rabbits with both human PD-L1 protein and cells transiently expressing human PD-L1 on the cell surface. Rabbits are known to create antibodies of high affinity, diversity and specificity (Weber et al. Exp. Mol. Med. 49:e305). B cells from immunized animals were cultured in vitro and screened for the production of anti-PD-L1 antibodies. The antibody variable genes were isolated using recombinant DNA techniques and the resulting antibodies were expressed recombinantly and further screened for desired features such as ability to inhibit the binding of PD-L1 to PD-1, the ability to bind to non-human primate PD-L1 and the ability to enhance human T-cell activation. This general method of antibody discovery is similar to that described in Seeber et al. PLOS One. 9:e86184 (2014).
[0065] The term "antigen- or epitope-binding portion or fragment" refers to fragments of an antibody that are capable of binding to an antigen (PD-L1 in this case). These fragments may be capable of the antigen-binding function and additional functions of the intact antibody. Examples of binding fragments include, but are not limited to a single-chain Fv fragment (scFv) consisting of the VL and VH domains of a single arm of an antibody connected in a single polypeptide chain by a synthetic linker or a Fab fragment which is a monovalent fragment consisting of the VL, constant light (CL), VH and constant heavy 1 (CH1) domains. Antibody fragments can be even smaller sub-fragments and can consist of domains as small as a single CDR domain, in particular the CDR3 regions from either the VL and/or VH domains (for example see Beiboer et al., J. Mol. Biol. 296:833-49 (2000)). Antibody fragments are produced using conventional methods known to those skilled in the art. The antibody fragments are can be screened for utility using the same techniques employed with intact antibodies.
[0066] The "antigen- or epitope-binding fragments" can be derived from an antibody of the present disclosure by a number of art-known techniques. For example, purified monoclonal antibodies can be cleaved with an enzyme, such as pepsin, and subjected to HPLC gel filtration. The appropriate fraction containing Fab fragments can then be collected and concentrated by membrane filtration and the like. For further description of general techniques for the isolation of active fragments of antibodies, see for example, Khaw, B. A. et al. J. Nucl. Med. 23:1011-1019 (1982); Rousseaux et al. Methods Enzymology, 121:663-69, Academic Press, 1986.
[0067] Papain digestion of antibodies produces two identical antigen binding fragments, called "Fab" fragments, each with a single antigen binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab')2 fragment that has two antigen combining sites and is still capable of cross-linking antigen.
[0068] The Fab fragment may contain the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other, chemical couplings of antibody fragments are also known.
[0069] "Fv" is the minimum antibody fragment which contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
[0070] The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda (A), based on the amino acid sequences of their constant domains.
[0071] Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG-1, IgG-2, IgG-3, and IgG-4; IgA-1 and IgA-2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called a, delta, epsilon, y, and p, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.
[0072] A "humanized antibody" refers to a type of engineered antibody having its CDRs derived from a non-human donor immunoglobulin, the remaining immunoglobulin-derived parts of the molecule being derived from one (or more) human immunoglobulin(s). In addition, framework support residues may be altered to preserve binding affinity. Methods to obtain "humanized antibodies" are well known to those skilled in the art. (see, e.g., Queen et al., Proc. Natl Acad Sci USA, 86:10029-10032 (1989), Hodgson et al., Bio/Technology, 9:421 (1991)). In one embodiment, the "humanized antibody" may be obtained by genetic engineering approach that enables production of affinity-matured humanlike polyclonal antibodies in large animals such as, for example, rabbits (see, e.g. U.S. Pat. No. 7,129,084).
[0073] The terms "polypeptide", "peptide", and "protein", as used herein, are interchangeable and are defined to mean a biomolecule composed of amino acids linked by a peptide bond.
[0074] The terms "a", "an" and "the" as used herein are defined to mean "one or more" and include the plural unless the context is inappropriate.
[0075] By "isolated" is meant a biological molecule free from at least some of the components with which it naturally occurs. "Isolated," when used to describe the various polypeptides disclosed herein, means a polypeptide that has been identified and separated and/or recovered from a cell or cell culture from which it was expressed. Ordinarily, an isolated polypeptide will be prepared by at least one purification step. An "isolated antibody," refers to an antibody which is substantially free of other antibodies having different antigenic specificities.
[0076] "Recombinant" means the antibodies are generated using recombinant nucleic acid techniques in exogeneous host cells.
[0077] The term "antigen" refers to an entity or fragment thereof which can induce an immune response in an organism, particularly an animal, more particularly a mammal including a human. The term includes immunogens and regions thereof responsible for antigenicity or antigenic determinants.
[0078] Also as used herein, the term "immunogenic" refers to substances which elicit or enhance the production of antibodies, T-cells or other reactive immune cells directed against an immunogenic agent and contribute to an immune response in humans or animals. An immune response occurs when an individual produces sufficient antibodies, T-cells and other reactive immune cells against administered immunogenic compositions of the present disclosure to moderate or alleviate the disorder to be treated.
[0079] "Specific binding" or "specifically binds to" or is "specific for" a particular antigen or an epitope means binding that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding activity. For example, specific binding can be determined by competition with a control molecule that is similar to the target.
[0080] Specific binding for a particular antigen or an epitope can be exhibited, for example, by an antibody having a KD for an antigen or epitope of at least about 10-4 M, at least about 10-5 M, at least about 10-6 M, at least about 10-7 M, at least about 10-8 M, at least about 10-9, alternatively at least about 10-10 M, at least about 10-11 M, at least about 10-12 M, or greater, where KD refers to a dissociation rate of a particular antibody-antigen interaction. In some embodiments, an antibody that specifically binds an antigen will have a KD that is 20-, 50-, 100-, 500-, 1000-, 5,000-, 10,000- or more times greater for a control molecule relative to the antigen or epitope.
[0081] Also, specific binding for a particular antigen or an epitope can be exhibited, for example, by an antibody having a KA or Ka for an antigen or epitope of at least 20-, 50-, 100-, 500-, 1000-, 5,000-, 10,000- or more times greater for the epitope relative to a control, where KA or Ka refers to an association rate of a particular antibody-antigen interaction.
[0082] "Homology" between two sequences is determined by sequence identity. If two sequences which are to be compared with each other differ in length, sequence identity preferably relates to the percentage of the nucleotide residues of the shorter sequence which are identical with the nucleotide residues of the longer sequence. Sequence identity can be determined conventionally with the use of computer programs. The deviations appearing in the comparison between a given sequence and the above-described sequences of the disclosure may be caused for instance by addition, deletion, substitution, insertion or recombination.
[0083] While the present disclosure has been described with reference to particular embodiments or examples, it may be understood that the embodiments are illustrative and that the disclosure scope is not so limited. Alternative embodiments of the present disclosure may become apparent to those having ordinary skill in the art to which the present disclosure pertains. Such alternate embodiments are considered to be encompassed within the scope of the present disclosure. Accordingly, the scope of the present disclosure is defined by the appended claims and is supported by the foregoing description. All references cited or referred to in this disclosure are hereby incorporated by reference in their entireties.
TABLE-US-00008 SEQUENCE LIST SEQ ID Description 1 anti-CD3 284A10 VHv1 nt 2 anti-CD3 284A10 VHv1 aa 3 anti-CD3 284A10 VLv1 nt 4 anti-CD3 284A10 VLv1 aa 5 anti-CD3 48008 VHv1 nt 6 anti-CD3 48008 VHv1 aa 7 anti-CD3 48008 VLv1 nt 8 anti-CD3 48008 VLv1 aa 9 anti-PD-L1 PL23C06 VHv3 nt 10 anti-PD-L1 PL23C06 VHv3 aa 11 anti-PD-L1 PL23C06 VLv2 nt 12 anti-PD-L1 PL23C06 VLv2 aa 13 anti-4-1BB 420H5 VHv3 nt 14 anti-4-1BB 420H5 VHv3 aa 15 anti-4-1BB 420H5 VLv3 nt 16 anti-4-1BB 420H5 VHLv3 aa 17 anti-4-1BB 466F6 VHv2 nt 18 anti-4-1BB 466F6 VHv2 aa 19 anti-4-1BB 466F6 VLv5 nt 20 anti-4-1BB 466F6 VLv5 aa 21 anti-4-1BB 460C3 VHv1 nt 22 anti-4-1BB 460C3 VHv1 aa 23 anti-4-1BB 460C3 VLv1 nt 24 anti-4-1BB 460C3 VLv1 aa 25 anti-ROR1 324C6 VHv2 nt 26 anti-ROR1 324C6 VHv2 aa 27 anti-ROR1 324C6 VLv1 nt 28 anti-ROR1 324C6 VLv1 aa 29 anti-ROR1 323H7 VHv4 nt 30 anti-ROR1 323H7 VHv4 aa 31 anti-ROR1 323H7 VLv1 nt 32 anti-ROR1 323H7 VLv1 aa 33 anti-ROR1 338H4 VHv3 nt 34 anti-ROR1 338H4 VHv3 aa 35 anti-ROR1 338H4 VLv4 nt 36 anti-ROR1 338H4 VLv4 aa 37 anti-ROR1 330F11 VHv1 nt 38 anti-ROR1 330F11 VHv1 aa 39 anti-ROR1 330F11 VLv1 nt 40 anti-ROR1 330F11 VLv1 aa 41 anti-FITC 4-4-20 VH nt 42 anti-FITC 4-4-20 VH aa 43 anti-FITC 4-4-20 VL nt 44 anti-FITC 4-4-20 VL aa 45 human IgG1 null2 (G1m-fa with ADCC/CDC null mutations) nt 46 human IgG1 null2 (G1m-fa with ADCC/CDC null mutations) aa 47 human Ig Kappa nt 48 human Ig Kappa aa 49 SI-35E18 (460C3-L1H1-scFv .times. PL230C6-Fab .times. 323H7-H4L1-scFv .times. 284A10-H1L1-scFv) heavy chain nt 50 SI-35E18 (460C3-L1H1-scFv .times. PL230C6-Fab .times. 323H7-H4L1-scFv .times. 284A10-H1L1-scFv) heavy chain aa 51 SI-35E18 (460C3-L1H1-scFv .times. PL230C6-Fab .times. 323H7-H4L1-scFv .times. 284A10-H1L1-scFv) light chain nt 52 SI-35E18 (460C3-L1H1-scFv .times. PL230C6-Fab .times. 323H7-H4L1-scFv .times. 284A10-H1L1-scFv) light chain aa >SEQ ID 01 anti-CD3 284A10 VHv1 nt GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTC TGGATTCACCATCAGTACCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAG TCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTCC- AA GAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGCGCGACGGTG- G ATCATCTGCTATTACTAGTAACAACATTTGGGGCCAAGGAACTCTGGTCACCGTTTCTTCA >SEQ ID 02 anti-CD3 284A10 VHv1 aa EVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISRDNS- KNTLY LQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSS >SEQ ID 03 anti-CD3 284A10 VLv1 nt GACGTCGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAATTGCCAAGC- CA GTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAA- G CATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATC- A GCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTA- AATT CTTTCGGCGGAGGGACCAAGGTGGAGATCAAA >SEQ ID 04 anti-CD3 284A10 VLv1 aa DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLT- ISSLQPD DFATYYCQGYFYFISRTYVNSFGGGTKVEIK >SEQ ID 05 anti-CD3 480C8 VHv1 nt GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTC TGGAATCGACCTCAGTAGCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAG TCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTCC- AA GAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGCGCGACGGTG- G ATCATCTGCTATTAATAGTAAGAACATTTGGGGCCAAGGAACTCTGGTCACCGTTTCTTCA >SEQ ID 06 anti-CD3 480C8 VHv1 aa EVQLVESGGGLVQPGGSLRLSCAASGIDLSSNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISRDNS- KNTLY LQMNSLRAEDTAVYYCARDGGSSAINSKNIWGQGTLVTVSS >SEQ ID 07 anti-CD3 480C8 VLv1 nt GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAAGC- CA GTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAA- G CATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATC- A GCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTA- AATG CTTTCGGCGGAGGGACCAAGGTGGAGATCAAA >SEQ ID 08 anti-CD3 480C8 VLv1 aa DIQMTQSPSTLSASVGDRVTITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLT- ISSLQPD DFATYYCQGYFYFISRTYVNAFGGGTKVEIK >SEQ ID 09 anti-PD-L1 PL230C6 VHv3 nt CAGTCGGTGGAGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACAGCCTCTGG AATCGACCTTAATACCTACGACATGATCTGGGTCCGCCAGGCTCCAGGCAAGGGGCTAGAGTGGGTTGGAATCA- T TACTTATAGTGGTAGTAGATACTACGCGAACTGGGCGAAAGGCCGATTCACCATCTCCAAAGACAATACCAAGA- A CACGGTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCCAGAGATTATATGA- G TGGTTCCCACTTGTGGGGCCAGGGAACCCTGGTCACCGTCTCTAGT >SEQ ID 10 anti-PD-L1 PL230C6 VHv3 aa QSVEESGGGLVQPGGSLRLSCTASGIDLNTYDMIWVRQAPGKGLEWVGIITYSGSRYYANWAKGRFTISKDNTK- NTVY LQMNSLRAEDTAVYYCARDYMSGSHLWGQGTLVTVSS >SEQ ID 11 anti-PD-L1 PL230C6 VLv2 nt GCCTATGATATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCAAGTGTCAGGC- CA GTGAGGACATTTATAGCTTCTTGGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCATTCT- GC ATCCTCTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCA- GC AGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCAACAGGGTTATGGTAAAAATAATGTTGATAATGCTTT- CG GCGGAGGGACCAAGGTGGAGATCAAA >SEQ ID 12 anti-PD-L1 PL230C6 VLv2 aa AYDMTQSPSSVSASVGDRVTIKCQASEDIYSFLAWYQQKPGKAPKLLIHSASSLASGVPSRFSGSGSGTDFTLT- ISSLQPE DFATYYCQQGYGKNNVDNAFGGGTKVEIK >SEQ ID 13 anti-4-1BB 420H5 VHv3 nt CAGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGG ATTCTCCTTCAGTAGCAACTACTGGATATGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCAT- G CATTTATGTTGGTAGTAGTGGTGACACTTACTACGCGAGCTCCGCGAAAGGCCGGTTCACCATCTCCAGAGACA- AT TCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGAGA- T AGTAGTAGTTATTATATGTTTAACTTGTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGC >SEQ ID 14 anti-4-1BB 420H5 VHv3 aa QSLVESGGGLVQPGGSLRLSCAASGFSFSSNYWICWVRQAPGKGLEWIACIYVGSSGDTYYASSAKGRFTISRD- NSKNT LYLQMNSLRAEDTAVYYCARDSSSYYMFNLWGQGTLVTVSS >SEQ ID 15 anti-4-1BB 420H5 VLv3 nt GCCCTTGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAATTGCCAGGC- CA GTGAGGACATTGATACCTATTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTTTTAT- GC ATCCGATCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCA- GC AGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGGCGGTTACTATACTAGTAGTGCTGATACGAGGGG- TG CTTTCGGCGGAGGGACCAAGGTGGAGATCAAA >SEQ ID 16 anti-4-1BB 420H5 VLv3 aa ALVMTQSPSTLSASVGDRVTINCQASEDIDTYLAWYQQKPGKAPKLLIFYASDLASGVPSRFSGSGSGTEFTLT- ISSLQPD DFATYYCQGGYYTSSADTRGAFGGGTKVEIK >SEQ ID 17 anti-4-1BB 466F6 VHv2 nt CGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACAGCCTCTGG- A TTCACCATCAGTAGCTACCACATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTACATCGGAACCAT- T AGTAGTGGTGGTAATGTATACTACGCGAGCTCCGCGAGAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGAA- C ACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTA- T
AGTGATCCTATGTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGC >SEQ ID 18 anti-4-1BB 466F6 VHv2 aa RSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKGLEYIGTISSGGNVYYASSARGRFTISRPSSK- NTVDLQ MNSLRAEDTAVYYCARDSGYSDPMWGQGTLVTVSS >SEQ ID 19 anti-4-1BB 466F6 VLv5 nt GACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGC- CA GTCAGAACATTAGGACTTACTTATCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCT- GC AGCCAATCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCA- GC GACCTGGAGCCTGGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTTGGCGGTGC- TTT CGGCGGAGGGACCAAGGTGGAGATCAAA >SEQ ID 20 anti-4-1BB 466F6 VLv5 aa DVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLT- ISDLEP GDAATYYCQSTYLGTDYVGGAFGGGTKVEIK >SEQ ID 21 anti-4-1BB 460C3 VHv1 nt GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTC- T GGAATCGACTTCAGTAGGAGATACTACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGC ATGCATATATACTGGTAGCCGCGATACTCCTCACTACGCGAGCTCCGCGAAAGGCCGGTTCACCATCTCCAGAG- AC AATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAG- A GAAGGTAGCCTGTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGC >SEQ ID 22 anti-4-1BB 460C3 VHv1 aa EVQLLESGGGLVQPGGSLRLSCAASGIDFSRRYYMCWVRQAPGKGLEWIACIYTGSRDTPHYASSAKGRFTISR- DNSKN TLYLQMNSLRAEDTAVYYCAREGSLWGQGTLVTVSS >SEQ ID 23 anti-4-1BB 460C3 VLv1 nt GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGTC- CA GTCAGAGTGTTTATAGTAACTGGTTCTCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTAT- TC TGCATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCA- TC AGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCGCAGGCGGTTACAATACTGTTATTGATACTTTTGC- TTT CGGCGGAGGGACCAAGGTGGAGATCAAA >SEQ ID 24 anti-4-1BB 460C3 VLv1 aa DIQMTQSPSTLSASVGDRVTITCQSSQSVYSNWFSWYQQKPGKAPKLLIYSASTLASGVPSRFSGSGSGTEFTL- TISSLQP DDFATYYCAGGYNTVIDTFAFGGGTKVEIK >SEQ ID 25 anti-ROR1 324C6 VHv2 nt CAGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACTGCCTCTGG- A TTCTCCCTCAGTAGGTACTACATGACCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAACCAT- T TATACTAGTGGTAGTACATGGTACGCGAGCTGGACAAAAGGCAGATTCACCATCTCCAAAGACAATACCAAGAA- C ACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGATCCTATTATGG- C GGTGATAAGACTGGTTTAGGCATCTGGGGCCAGGGAACTCTGGTTACCGTCTCTTCA >SEQ ID 26 anti-ROR1 324C6 VHv2 nt QSLVESGGGLVQPGGSLRLSCTASGFSLSRYYMTWVRQAPGKGLEWIGTIYTSGSTWYASWTKGRFTISKDNTK- NTVD LQMNSLRAEDTAVYYCARSYYGGDKTGLGIWGQGTLVTVSS >SEQ ID 27 anti-ROR1 324C6 VLv1 nt GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGC- CA GTCAGAGCATTGATAGTTGGTTATCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAG- GC ATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCA- GC AGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAATCTGCTTATGGTGTTAGTGGTACTAGTAGTTATTT- ATA TACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA >SEQ ID 28 anti-ROR1 324C6 VLv1 aa DIQMTQSPSTLSASVGDRVTITCQASQSIDSWLSWYQQKPGKAPKLLIYQASTLASGVPSRFSGSGSGTEFTLT- ISSLQPD DFATYYCQSAYGVSGTSSYLYTFGGGTKVEIK >SEQ ID 29 anti-ROR1 323H7 VHv4 nt GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTC- T GGATTCACCATCAGTCGCTACCACATGACTTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGACA- T ATTTATGTTAATAATGATGACACAGACTACGCGAGCTCCGCGAAAGGCCGGTTCACCATCTCCAGAGACAATTC- CA AGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCACCTATTTCTGTGCGAGATTGGAT- G TTGGTGGTGGTGGTGCTTATATTGGGGACATCTGGGGCCAGGGAACTCTGGTTACCGTCTCTTCA >SEQ ID 30 anti-ROR1 323H7 VHv4 aa EVQLLESGGGLVQPGGSLRLSCAASGFTISRYHMTWVRQAPGKGLEWIGHIYVNNDDTDYASSAKGRFTISRDN- SKNT LYLQMNSLRAEDTATYFCARLDVGGGGAYIGDIWGQGTLVTVSS >SEQ ID 31 anti-ROR1 323H7 VLv1 nt GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGTC- CA GTCAGAGTGTTTATAACAACAACGACTTAGCCTGGTATCAGCAGAAACCAGGGAAAGTTCCTAAGCTCCTGATC- TA TTATGCTTCCACTCTGGCATCTGGGGTCCCATCTCGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCA- CCA TCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATTACTGTGCAGGCGGTTATGATACGGATGGTCTTGATACG- TT TGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAA >SEQ ID 32 anti-ROR1 323H7 VLv1 aa DIQMTQSPSSLSASVGDRVTITCQSSQSVYNNNDLAWYQQKPGKVPKLLIYYASTLASGVPSRFSGSGSGTDFT- LTISSL QPEDVATYYCAGGYDTDGLDTFAFGGGTKVEIK >SEQ ID 33 anti-ROR1 338H4 VHv3 nt GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACTGCCTC- T GGATTCTCCCTCAGTAGCTATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAGGGGGCTGGAGTGGATCGGAAT CATTTATGCTAGTGGTAGCACATACTACGCGAGCTCGGCGAAAGGCAGATTCACCATCTCCAAAGACAATACCA- AG AACACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAATTTATGA- C GGCATGGACCTCTGGGGCCAGGGAACTCTGGTTACCGTCTCTTCA >SEQ ID 34 anti-ROR1 338H4 VHv3 aa EVQLVESGGGLVQPGGSLRLSCTASGFSLSSYAMSWVRQAPGRGLEWIGIIYASGSTYYASSAKGRFTISKDNT- KNTVDL QMNSLRAEDTAVYYCARIYDGMDLWGQGTLVTVSS >SEQ ID 35 anti-ROR1 338H4 VLv4 nt GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAATTGCCAGGC- CA GTCAGAACATTTACAGCTACTTATCCTGGTATCAGCAGAAACCAGGGAAAGTTCCTAAGCGCCTGATCTATCTG- GC ATCTACTCTGGCATCTGGGGTCCCATCTCGGTTCAGTGGCAGTGGATCTGGGACAGATTACACTCTCACCATCA- GC AGCCTGCAGCCTGAAGATGTTGCAACTTATTACTGTCAAAGCAATTATAACGGTAATTATGGTTTCGGCGGAGG- GA CCAAGGTGGAGATCAAA >SEQ ID 36 anti-ROR1 338H4 VLv4 aa DIQMTQSPSSLSASVGDRVTINCQASQNIYSYLSWYQQKPGKVPKRLIYLASTLASGVPSRFSGSGSGTDYTLT- ISSLQPE DVATYYCQSNYNGNYGFGGGTKVEIK >SEQ ID 37 anti-ROR1 330F11 VHv1 nt GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTC TGGATTCTCCCTCAATAACTACTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAA CCATTAGTAGTGGTGCGTATACATGGTTCGCCACCTGGGCGACAGGCAGATTCACCATCTCCAGAGACAATTCC- AA GAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGATATTCTT- CT ACTACTGATTGGACCTACTTTAACATCTGGGGCCAGGGAACTCTGGTTACCGTCTCTTCA >SEQ ID 38 anti-ROR1 330F11 VHv1 aa EVQLVESGGGLVQPGGSLRLSCAASGFSLNNYWMSWVRQAPGKGLEWIGTISSGAYTWFATWATGRFTISRDNS- KN TLYLQMNSLRAEDTAVYYCARYSSTTDWTYFNIWGQGTLVTVSS >SEQ ID 39 anti-ROR1 330F11 VLv1 nt GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGC- CA GTCAGAGCATTAATAACTACTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAGG- GC ATCCACTCTGGAATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCA- GC AGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAAGCTATAATGGTGTTGGTAGGACTGCTTTCGGCGG- AG GGACCAAGGTGGAGATCAAA >SEQ ID 40 anti-ROR1 330F11 VLv1 aa DIQMTQSPSTLSASVGDRVTITCQASQSINNYLAWYQQKPGKAPKLLIYRASTLESGVPSRFSGSGSGTEFTLT- ISSLQPD DFATYYCQSYNGVGRTAFGGGTKVEIK >SEQ ID 41 anti-FITC 4-4-20 VH nt GAGGTGAAGCTGGATGAGACTGGAGGAGGCTTGGTGCAACCTGGGAGGCCCATGAAACTCTCCTGTGTTGCCTC- T GGATTCACTTTTAGTGACTACTGGATGAACTGGGTCCGCCAGTCTCCAGAGAAAGGACTGGAGTGGGTAGCACA- A ATTAGAAACAAACCTTATAATTATGAAACATATTATTCAGATTCTGTGAAAGGCAGATTCACCATCTCAAGAGA- TG ATTCCAAAAGTAGTGTCTACCTGCAAATGAACAACTTAAGAGTTGAAGACATGGGTATCTATTACTGTACGGGT- TC TTACTATGGTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA >SEQ ID 42 anti-FITC 4-4-20 VH aa EVKLDETGGGLVQPGRPMKLSCVASGFTFSDYWMNWVRQSPEKGLEWVAQIRNKPYNYETYYSDSVKGRFTISR- DDS KSSVYLQMNNLRVEDMGIYYCTGSYYGMDYWGQGTSVTVSS >SEQ ID 43 anti-FITC 4-4-20 VL nt GATGTCGTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCAAGCCTCCATCTCTTGCAGATC- TAG TCAGAGCCTTGTACACAGTAATGGAAACACCTATTTACGTTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAGG- TC CTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTT- CA CACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGGAGTTTATTTCTGCTCTCAAAGTACACATGTTCCGTGG- AC GTTCGGTGGAGGCACCAAGCTGGAAATCAAA >SEQ ID 44 anti-FITC 4-4-20 VL aa DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLRWYLQKPGQSPKVLIYKVSNRFSGVPDRFSGSGSGT- DFTLKI SRVEAEDLGVYFCSQSTHVPWTFGGGTKLEIK >SEQ ID 45 human IgG1 null (G1m-fa with ADCC/CDC null mutations) nt GCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCT- G GGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGT- G CACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAG- CTT GGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCA AATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTC- TT CCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCC- A CGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGG AGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAG- G AGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAG- C CCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGC- C TGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAG ACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTG- GC AGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCC- CT GTCTCCGGGT >SEQ ID 46 human IgG1 null (G1m-fa with ADCC/CDC null mutations) aa ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSS- SLGTQTY ICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE- VKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTL- PPSRD
ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE- ALHN HYTQKSLSLSPG >SEQ ID 47 human Ig Kappa nt CGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGT- TGT GTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTA- A CTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCA AAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAG- A GCTTCAACAGGGGAGAGTGT >SEQ ID 48 human Ig Kappa aa RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL- SKADYE KHKVYACEVTHQGLSSPVTKSFNRGEC >SEQ ID 49 SI-35E18 (460C3-L1H1-scFv .times. PL230C6-Fab .times. 323H7-H4L1-scFv .times. 284A10- H1L1-scFv) heavy chain nt GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGTC- CA GTCAGAGTGTTTATAGTAACTGGTTCTCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTAT- TC TGCATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCA- TC AGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCGCAGGCGGTTACAATACTGTTATTGATACTTTTGC- TTT CGGCGGAGGGACCAAGGTGGAGATCAAAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTC CGGCGGTGGAGGATCAGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGA CTCTCCTGTGCAGCCTCTGGAATCGACTTCAGTAGGAGATACTACATGTGCTGGGTCCGCCAGGCTCCAGGGAA- G GGGCTGGAGTGGATCGCATGCATATATACTGGTAGCCGCGATACTCCTCACTACGCGAGCTCCGCGAAAGGCCG- G TTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGC- C GTATATTACTGTGCGAGAGAAGGTAGCCTGTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGCGGCGGTGGAGG GTCCGGCGGTGGTGGATCCCAGTCGGTGGAGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGA CTCTCCTGTACAGCCTCTGGAATCGACCTTAATACCTACGACATGATCTGGGTCCGCCAGGCTCCAGGCAAGGG- GC TAGAGTGGGTTGGAATCATTACTTATAGTGGTAGTAGATACTACGCGAACTGGGCGAAAGGCCGATTCACCATC- T CCAAAGACAATACCAAGAACACGGTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTAC- T GTGCCAGAGATTATATGAGTGGTTCCCACTTGTGGGGCCAGGGAACCCTGGTCACCGTCTCTAGTGCTAGCACC- A AGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTG- G TCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTC- C CGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACC- CA GACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTG- A CAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAA- AA CCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCC- T GAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGT ACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAG- T GCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAA- C CACAGGTGTATACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAA- G GCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGG- G AACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCC- GG GTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCC TGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCATCAGTCGCTACCACATGACTTGGGTCCGCC- AG GCTCCAGGGAAGGGGCTGGAGTGGATCGGACATATTTATGTTAATAATGATGACACAGACTACGCGAGCTCCGC- G AAAGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGA- G GACACGGCCACCTATTTCTGTGCGAGATTGGATGTTGGTGGTGGTGGTGCTTATATTGGGGACATCTGGGGCCA- G GGAACTCTGGTTACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCG GTGGAGGATCAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATC- AC TTGCCAGTCCAGTCAGAGTGTTTATAACAACAACGACTTAGCCTGGTATCAGCAGAAACCAGGGAAAGTTCCTA- AG CTCCTGATCTATTATGCTTCCACTCTGGCATCTGGGGTCCCATCTCGGTTCAGTGGCAGTGGATCTGGGACAGA- TTT CACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATTACTGTGCAGGCGGTTATGATACGGATG- GT CTTGATACGTTTGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAAGGCGGTGGAGGGTCCGGCGGTGGTGGATC CGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCT CTGGATTCACCATCAGTACCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGA GTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTC- CA AGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGCGCGACGGT- G GATCATCTGCTATTACTAGTAACAACATTTGGGGCCAAGGAACTCTGGTCACCGTTTCTTCAGGCGGTGGCGGT- AG TGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGACGTCGTGATGACCCAGTCTCCTTCCA CCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCC- TG GTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCAT- C AAGGTTCAGCGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAA- CT TATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCGGAGGGACCAAGGTGGA- GAT CAAA >SEQ ID 50 SI-35E18 (460C3-L1H1-scFv .times. PL230C6-Fab .times. 323H7-H4L1-scFv .times. 284A10- H1L1-scFv) heavy chain aa DIQMTQSPSTLSASVGDRVTITCQSSQSVYSNWFSWYQQKPGKAPKLLIYSASTLASGVPSRFSGSGSGTEFTL- TISSLQP DDFATYYCAGGYNTVIDTFAFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAA- SGI DFSRRYYMCWVRQAPGKGLEWIACIYTGSRDTPHYASSAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARE- GSLW GQGTLVTVSSGGGGSGGGGSQSVEESGGGLVQPGGSLRLSCTASGIDLNTYDMIWVRQAPGKGLEWVGIITYSG- SRYY ANWAKGRFTISKDNTKNTVYLQMNSLRAEDTAVYYCARDYMSGSHLWGQGTLVTVSSASTKGPSVFPLAPSSKS- TSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV- DKRVEP KSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP- REEQ YNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV- KGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGG- GSG GGGSEVQLLESGGGLVQPGGSLRLSCAASGFTISRYHMTWVRQAPGKGLEWIGHIYVNNDDTDYASSAKGRFTI- SRDN SKNTLYLQMNSLRAEDTATYFCARLDVGGGGAYIGDIWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQ- S PSSLSASVGDRVTITCQSSQSVYNNNDLAWYQQKPGKVPKLLIYYASTLASGVPSRFSGSGSGTDFTLTISSLQ- PEDVATY YCAGGYDTDGLDTFAFGGGTKVEIKGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQ- AP GKGLEWIGVITGRDITYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTL- VTVSS GGGGSGGGGSGGGGSGGGGSDVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKL- ASG VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIK >SEQ ID 51 SI-35E18 (460C3-L1H1-scFv .times. PL230C6-Fab .times. 323H7-H4L1-scFv .times. 284A10- H1L1-scFv) light chain nt GCCTATGATATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCAAGTGTCAGGC- CA GTGAGGACATTTATAGCTTCTTGGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCATTCT- GC ATCCTCTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCA- GC AGCCTGCAGCCTGAAGATTTTGCAACTTACTATTGTCAACAGGGTTATGGTAAAAATAATGTTGATAATGCTTT- CG GCGGAGGGACCAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAG- C AGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGG- AA GGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACA GCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCAT- C AGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT >SEQ ID 52 SI-35E18 (460C3-L1H1-scFv .times. PL230C6-Fab .times. 323H7-H4L1-scFv .times. 284A10- H1L1-scFv) light chain aa AYDMTQSPSSVSASVGDRVTIKCQASEDIYSFLAWYQQKPGKAPKLLIHSASSLASGVPSRFSGSGSGTDFTLT- ISSLQPE DFATYYCQQGYGKNNVDNAFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN- ALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC CDR's underlined in amino acid sequences
Sequence CWU
1
1
521360DNAArtificial SequenceSynthesized 1gaggtgcagc tggtggagtc tgggggaggc
ttggtccagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt caccatcagt
accaatgcaa tgagctgggt ccgccaggct 120ccagggaagg ggctggagtg gatcggagtc
attactggtc gtgatatcac atactacgcg 180agctgggcga aaggcagatt caccatctcc
agagacaatt ccaagaacac gctgtatctt 240caaatgaaca gcctgagagc cgaggacacg
gctgtgtatt actgtgcgcg cgacggtgga 300tcatctgcta ttactagtaa caacatttgg
ggccaaggaa ctctggtcac cgtttcttca 3602120PRTArtificial
SequenceSynthesized 2Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Ser Thr Asn 20
25 30Ala Met Ser Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Ile 35 40
45Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala Ser Trp Ala Lys
50 55 60Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ser Lys Asn Thr Leu Tyr Leu65 70 75
80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys Ala 85 90 95Arg
Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn Asn Ile Trp Gly Gln
100 105 110Gly Thr Leu Val Thr Val Ser
Ser 115 1203336DNAArtificial SequenceSynthesized
3gacgtcgtga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc
60atcaattgcc aagccagtga gagcattagc agttggttag cctggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctatgaa gcatccaaac tggcatctgg ggtcccatca
180aggttcagcg gcagtggatc tgggacagag ttcactctca ccatcagcag cctgcagcct
240gatgattttg caacttatta ctgccaaggc tatttttatt ttattagtcg tacttatgta
300aattctttcg gcggagggac caaggtggag atcaaa
3364112PRTArtificial SequenceSynthesized 4Asp Val Val Met Thr Gln Ser Pro
Ser Thr Leu Ser Ala Ser Val Gly1 5 10
15Asp Arg Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Ser
Ser Trp 20 25 30Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35
40 45Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60Ser Gly
Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65
70 75 80Asp Asp Phe Ala Thr Tyr Tyr
Cys Gln Gly Tyr Phe Tyr Phe Ile Ser 85 90
95Arg Thr Tyr Val Asn Ser Phe Gly Gly Gly Thr Lys Val
Glu Ile Lys 100 105
1105360DNAArtificial SequenceSynthesized 5gaggtgcagc tggtggagtc
tgggggaggc ttggtccagc ctggggggtc cctgagactc 60tcctgtgcag cctctggaat
cgacctcagt agcaatgcaa tgagctgggt ccgccaggct 120ccagggaagg ggctggagtg
gatcggagtc attactggtc gtgatatcac atactacgcg 180agctgggcga aaggcagatt
caccatctcc agagacaatt ccaagaacac gctgtatctt 240caaatgaaca gcctgagagc
cgaggacacg gctgtgtatt actgtgcgcg cgacggtgga 300tcatctgcta ttaatagtaa
gaacatttgg ggccaaggaa ctctggtcac cgtttcttca 3606120PRTArtificial
SequenceSynthesized 6Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Asp Leu Ser Ser Asn 20
25 30Ala Met Ser Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Ile 35 40
45Gly Val Ile Thr Gly Arg Asp Ile Thr Tyr Tyr Ala Ser Trp Ala Lys
50 55 60Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ser Lys Asn Thr Leu Tyr Leu65 70 75
80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys Ala 85 90 95Arg
Asp Gly Gly Ser Ser Ala Ile Asn Ser Lys Asn Ile Trp Gly Gln
100 105 110Gly Thr Leu Val Thr Val Ser
Ser 115 1207336DNAArtificial SequenceSynthesized
7gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc
60atcacttgcc aagccagtga gagcattagc agttggttag cctggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctatgaa gcatccaaac tggcatctgg ggtcccatca
180aggttcagcg gcagtggatc tgggacagag ttcactctca ccatcagcag cctgcagcct
240gatgattttg caacttatta ctgccaaggc tatttttatt ttattagtcg tacttatgta
300aatgctttcg gcggagggac caaggtggag atcaaa
3368112PRTArtificial SequenceSynthesized 8Asp Ile Gln Met Thr Gln Ser Pro
Ser Thr Leu Ser Ala Ser Val Gly1 5 10
15Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Glu Ser Ile Ser
Ser Trp 20 25 30Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35
40 45Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60Ser Gly
Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65
70 75 80Asp Asp Phe Ala Thr Tyr Tyr
Cys Gln Gly Tyr Phe Tyr Phe Ile Ser 85 90
95Arg Thr Tyr Val Asn Ala Phe Gly Gly Gly Thr Lys Val
Glu Ile Lys 100 105
1109345DNAArtificial SequenceSynthesized 9cagtcggtgg aggagtctgg
gggaggcttg gtccagcctg gggggtccct gagactctcc 60tgtacagcct ctggaatcga
ccttaatacc tacgacatga tctgggtccg ccaggctcca 120ggcaaggggc tagagtgggt
tggaatcatt acttatagtg gtagtagata ctacgcgaac 180tgggcgaaag gccgattcac
catctccaaa gacaatacca agaacacggt gtatctgcaa 240atgaacagcc tgagagctga
ggacacggct gtgtattact gtgccagaga ttatatgagt 300ggttcccact tgtggggcca
gggaaccctg gtcaccgtct ctagt 34510115PRTArtificial
SequenceSynthesized 10Gln Ser Val Glu Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly Ser1 5 10 15Leu
Arg Leu Ser Cys Thr Ala Ser Gly Ile Asp Leu Asn Thr Tyr Asp 20
25 30Met Ile Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Val Gly 35 40
45Ile Ile Thr Tyr Ser Gly Ser Arg Tyr Tyr Ala Asn Trp Ala Lys Gly
50 55 60Arg Phe Thr Ile Ser Lys Asp Asn
Thr Lys Asn Thr Val Tyr Leu Gln65 70 75
80Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
Cys Ala Arg 85 90 95Asp
Tyr Met Ser Gly Ser His Leu Trp Gly Gln Gly Thr Leu Val Thr
100 105 110Val Ser Ser
11511330DNAArtificial SequenceSynthesized 11gcctatgata tgacccagtc
tccatcttcc gtgtctgcat ctgtaggaga cagagtcacc 60atcaagtgtc aggccagtga
ggacatttat agcttcttgg cctggtatca gcagaaacca 120gggaaagccc ctaagctcct
gatccattct gcatcctctc tggcatctgg ggtcccatca 180aggttcagcg gcagtggatc
tgggacagat ttcactctca ccatcagcag cctgcagcct 240gaagattttg caacttacta
ttgtcaacag ggttatggta aaaataatgt tgataatgct 300ttcggcggag ggaccaaggt
ggagatcaaa 33012110PRTArtificial
SequenceSynthesized 12Ala Tyr Asp Met Thr Gln Ser Pro Ser Ser Val Ser Ala
Ser Val Gly1 5 10 15Asp
Arg Val Thr Ile Lys Cys Gln Ala Ser Glu Asp Ile Tyr Ser Phe 20
25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40
45His Ser Ala Ser Ser Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60Ser Gly Ser Gly Thr Asp Phe Thr
Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Gly
Lys Asn Asn 85 90 95Val
Asp Asn Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
105 11013360DNAArtificial SequenceSynthesized
13cagtcgctgg tggagtctgg gggaggcttg gtacagcctg gggggtccct gagactctcc
60tgtgcagcct ctggattctc cttcagtagc aactactgga tatgctgggt ccgccaggct
120ccagggaagg ggctggagtg gatcgcatgc atttatgttg gtagtagtgg tgacacttac
180tacgcgagct ccgcgaaagg ccggttcacc atctccagag acaattccaa gaacacgctg
240tatctgcaaa tgaacagcct gagagccgag gacacggccg tatattactg tgcgagagat
300agtagtagtt attatatgtt taacttgtgg ggccagggaa ccctggtcac cgtctcgagc
36014120PRTArtificial SequenceSynthesized 14Gln Ser Leu Val Glu Ser Gly
Gly Gly Leu Val Gln Pro Gly Gly Ser1 5 10
15Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser
Ser Asn Tyr 20 25 30Trp Ile
Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35
40 45Ala Cys Ile Tyr Val Gly Ser Ser Gly Asp
Thr Tyr Tyr Ala Ser Ser 50 55 60Ala
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu65
70 75 80Tyr Leu Gln Met Asn Ser
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 85
90 95Cys Ala Arg Asp Ser Ser Ser Tyr Tyr Met Phe Asn
Leu Trp Gly Gln 100 105 110Gly
Thr Leu Val Thr Val Ser Ser 115
12015336DNAArtificial SequenceSynthesized 15gcccttgtga tgacccagtc
tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60atcaattgcc aggccagtga
ggacattgat acctatttag cctggtatca gcagaaacca 120gggaaagccc ctaagctcct
gatcttttat gcatccgatc tggcatctgg ggtcccatca 180aggttcagcg gcagtggatc
tgggacagaa ttcactctca ccatcagcag cctgcagcct 240gatgattttg caacttatta
ctgccaaggc ggttactata ctagtagtgc tgatacgagg 300ggtgctttcg gcggagggac
caaggtggag atcaaa 33616112PRTArtificial
SequenceSynthesized 16Ala Leu Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala
Ser Val Gly1 5 10 15Asp
Arg Val Thr Ile Asn Cys Gln Ala Ser Glu Asp Ile Asp Thr Tyr 20
25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40
45Phe Tyr Ala Ser Asp Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60Ser Gly Ser Gly Thr Glu Phe Thr
Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gly Gly Tyr Tyr
Thr Ser Ser 85 90 95Ala
Asp Thr Arg Gly Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 11017345DNAArtificial
SequenceSynthesized 17cggtcgctgg tggagtctgg gggaggcttg gtccagcctg
gggggtccct gagactctcc 60tgtacagcct ctggattcac catcagtagc taccacatgc
agtgggtccg ccaggctcca 120gggaaggggc tggagtacat cggaaccatt agtagtggtg
gtaatgtata ctacgcgagc 180tccgcgagag gcagattcac catctccaga ccctcgtcca
agaacacggt ggatcttcaa 240atgaacagcc tgagagccga ggacacggct gtgtattact
gtgcgagaga ctctggttat 300agtgatccta tgtggggcca gggaaccctg gtcaccgtct
cgagc 34518115PRTArtificial SequenceSynthesized 18Arg
Ser Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser1
5 10 15Leu Arg Leu Ser Cys Thr Ala
Ser Gly Phe Thr Ile Ser Ser Tyr His 20 25
30Met Gln Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr
Ile Gly 35 40 45Thr Ile Ser Ser
Gly Gly Asn Val Tyr Tyr Ala Ser Ser Ala Arg Gly 50 55
60Arg Phe Thr Ile Ser Arg Pro Ser Ser Lys Asn Thr Val
Asp Leu Gln65 70 75
80Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
85 90 95Asp Ser Gly Tyr Ser Asp
Pro Met Trp Gly Gln Gly Thr Leu Val Thr 100
105 110Val Ser Ser 11519333DNAArtificial
SequenceSynthesized 19gacgttgtga tgacccagtc tccatcttcc gtgtctgcat
ctgtaggaga cagagtcacc 60atcacctgtc aggccagtca gaacattagg acttacttat
cctggtatca gcagaaacca 120gggaaagccc ctaagctcct gatctatgct gcagccaatc
tggcatctgg ggtcccatca 180aggttcagcg gcagtggatc tgggacagat ttcactctca
ccatcagcga cctggagcct 240ggcgatgctg caacttacta ttgtcagtct acctatcttg
gtactgatta tgttggcggt 300gctttcggcg gagggaccaa ggtggagatc aaa
33320111PRTArtificial SequenceSynthesized 20Asp
Val Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys
Gln Ala Ser Gln Asn Ile Arg Thr Tyr 20 25
30Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Ala Ala Ala
Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55
60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asp
Leu Glu Pro65 70 75
80Gly Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Thr Tyr Leu Gly Thr Asp
85 90 95Tyr Val Gly Gly Ala Phe
Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105
11021345DNAArtificial SequenceSynthesized 21gaggtgcagc
tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag
cctctggaat cgacttcagt aggagatact acatgtgctg ggtccgccag 120gctccaggga
aggggctgga gtggatcgca tgcatatata ctggtagccg cgatactcct 180cactacgcga
gctccgcgaa aggccggttc accatctcca gagacaattc caagaacacg 240ctgtatctgc
aaatgaacag cctgagagcc gaggacacgg ccgtatatta ctgtgcgaga 300gaaggtagcc
tgtggggcca gggaaccctg gtcaccgtct cgagc
34522115PRTArtificial SequenceSynthesized 22Glu Val Gln Leu Leu Glu Ser
Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10
15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Asp Phe
Ser Arg Arg 20 25 30Tyr Tyr
Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 35
40 45Ile Ala Cys Ile Tyr Thr Gly Ser Arg Asp
Thr Pro His Tyr Ala Ser 50 55 60Ser
Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr65
70 75 80Leu Tyr Leu Gln Met Asn
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85
90 95Tyr Cys Ala Arg Glu Gly Ser Leu Trp Gly Gln Gly
Thr Leu Val Thr 100 105 110Val
Ser Ser 11523333DNAArtificial SequenceSynthesized 23gacatccaga
tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc
agtccagtca gagtgtttat agtaactggt tctcctggta tcagcagaaa 120ccagggaaag
cccctaagct cctgatctat tctgcatcca ctctggcatc tggggtccca 180tcaaggttca
gcggcagtgg atctgggaca gaattcactc tcaccatcag cagcctgcag 240cctgatgatt
ttgcaactta ttactgcgca ggcggttaca atactgttat tgatactttt 300gctttcggcg
gagggaccaa ggtggagatc aaa
33324111PRTArtificial SequenceSynthesized 24Asp Ile Gln Met Thr Gln Ser
Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10
15Asp Arg Val Thr Ile Thr Cys Gln Ser Ser Gln Ser Val
Tyr Ser Asn 20 25 30Trp Phe
Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu 35
40 45Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly
Val Pro Ser Arg Phe Ser 50 55 60Gly
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln65
70 75 80Pro Asp Asp Phe Ala Thr
Tyr Tyr Cys Ala Gly Gly Tyr Asn Thr Val 85
90 95Ile Asp Thr Phe Ala Phe Gly Gly Gly Thr Lys Val
Glu Ile Lys 100 105
11025357DNAArtificial SequenceSynthesized 25cagtcgctgg tggagtctgg
gggaggcttg gtccagcctg gggggtccct gagactctcc 60tgtactgcct ctggattctc
cctcagtagg tactacatga cctgggtccg ccaggctcca 120gggaaggggc tggagtggat
cggaaccatt tatactagtg gtagtacatg gtacgcgagc 180tggacaaaag gcagattcac
catctccaaa gacaatacca agaacacggt ggatcttcaa 240atgaacagcc tgagagccga
ggacacggct gtgtattact gtgcgagatc ctattatggc 300ggtgataaga ctggtttagg
catctggggc cagggaactc tggttaccgt ctcttca 35726119PRTArtificial
SequenceSynthesized 26Gln Ser Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly Ser1 5 10 15Leu
Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Leu Ser Arg Tyr Tyr 20
25 30Met Thr Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Ile Gly 35 40
45Thr Ile Tyr Thr Ser Gly Ser Thr Trp Tyr Ala Ser Trp Thr Lys Gly
50 55 60Arg Phe Thr Ile Ser Lys Asp Asn
Thr Lys Asn Thr Val Asp Leu Gln65 70 75
80Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
Cys Ala Arg 85 90 95Ser
Tyr Tyr Gly Gly Asp Lys Thr Gly Leu Gly Ile Trp Gly Gln Gly
100 105 110Thr Leu Val Thr Val Ser Ser
11527339DNAArtificial SequenceSynthesized 27gacatccaga tgacccagtc
tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc aggccagtca
gagcattgat agttggttat cctggtatca gcagaaacca 120gggaaagccc ctaagctcct
gatctatcag gcatccactc tggcatctgg ggtcccatca 180aggttcagcg gcagtggatc
tgggacagag ttcactctca ccatcagcag cctgcagcct 240gatgattttg caacttatta
ctgccaatct gcttatggtg ttagtggtac tagtagttat 300ttatatactt tcggcggagg
gaccaaggtg gagatcaaa 33928113PRTArtificial
SequenceSynthesized 28Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala
Ser Val Gly1 5 10 15Asp
Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Asp Ser Trp 20
25 30Leu Ser Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40
45Tyr Gln Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60Ser Gly Ser Gly Thr Glu Phe Thr
Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Ser Ala Tyr Gly
Val Ser Gly 85 90 95Thr
Ser Ser Tyr Leu Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile
100 105 110Lys29366DNAArtificial
SequenceSynthesized 29gaggtgcagc tgttggagtc tgggggaggc ttggtacagc
ctggggggtc cctgagactc 60tcctgtgcag cctctggatt caccatcagt cgctaccaca
tgacttgggt ccgccaggct 120ccagggaagg ggctggagtg gatcggacat atttatgtta
ataatgatga cacagactac 180gcgagctccg cgaaaggccg gttcaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac acggccacct
atttctgtgc gagattggat 300gttggtggtg gtggtgctta tattggggac atctggggcc
agggaactct ggttaccgtc 360tcttca
36630122PRTArtificial SequenceSynthesized 30Glu
Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1
5 10 15Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Phe Thr Ile Ser Arg Tyr 20 25
30His Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Ile 35 40 45Gly His Ile Tyr
Val Asn Asn Asp Asp Thr Asp Tyr Ala Ser Ser Ala 50 55
60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
Thr Leu Tyr65 70 75
80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Thr Tyr Phe Cys
85 90 95Ala Arg Leu Asp Val Gly
Gly Gly Gly Ala Tyr Ile Gly Asp Ile Trp 100
105 110Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115
12031339DNAArtificial SequenceSynthesized 31gacatccaga
tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc
agtccagtca gagtgtttat aacaacaacg acttagcctg gtatcagcag 120aaaccaggga
aagttcctaa gctcctgatc tattatgctt ccactctggc atctggggtc 180ccatctcggt
tcagtggcag tggatctggg acagatttca ctctcaccat cagcagcctg 240cagcctgaag
atgttgcaac ttattactgt gcaggcggtt atgatacgga tggtcttgat 300acgtttgctt
tcggcggagg gaccaaggtg gagatcaaa
33932113PRTArtificial SequenceSynthesized 32Asp Ile Gln Met Thr Gln Ser
Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10
15Asp Arg Val Thr Ile Thr Cys Gln Ser Ser Gln Ser Val
Tyr Asn Asn 20 25 30Asn Asp
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu 35
40 45Leu Ile Tyr Tyr Ala Ser Thr Leu Ala Ser
Gly Val Pro Ser Arg Phe 50 55 60Ser
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu65
70 75 80Gln Pro Glu Asp Val Ala
Thr Tyr Tyr Cys Ala Gly Gly Tyr Asp Thr 85
90 95Asp Gly Leu Asp Thr Phe Ala Phe Gly Gly Gly Thr
Lys Val Glu Ile 100 105
110Lys33345DNAArtificial SequenceSynthesized 33gaggtgcagc tggtggagtc
tgggggaggc ttggtccagc ctggggggtc cctgagactc 60tcctgtactg cctctggatt
ctccctcagt agctatgcaa tgagctgggt ccgccaggct 120ccagggaggg ggctggagtg
gatcggaatc atttatgcta gtggtagcac atactacgcg 180agctcggcga aaggcagatt
caccatctcc aaagacaata ccaagaacac ggtggatctt 240caaatgaaca gcctgagagc
cgaggacacg gctgtgtatt actgtgcgag aatttatgac 300ggcatggacc tctggggcca
gggaactctg gttaccgtct cttca 34534115PRTArtificial
SequenceSynthesized 34Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Leu Ser Ser Tyr 20
25 30Ala Met Ser Trp Val Arg Gln Ala
Pro Gly Arg Gly Leu Glu Trp Ile 35 40
45Gly Ile Ile Tyr Ala Ser Gly Ser Thr Tyr Tyr Ala Ser Ser Ala Lys
50 55 60Gly Arg Phe Thr Ile Ser Lys Asp
Asn Thr Lys Asn Thr Val Asp Leu65 70 75
80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys Ala 85 90 95Arg
Ile Tyr Asp Gly Met Asp Leu Trp Gly Gln Gly Thr Leu Val Thr
100 105 110Val Ser Ser
11535321DNAArtificial SequenceSynthesized 35gacatccaga tgacccagtc
tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcaattgcc aggccagtca
gaacatttac agctacttat cctggtatca gcagaaacca 120gggaaagttc ctaagcgcct
gatctatctg gcatctactc tggcatctgg ggtcccatct 180cggttcagtg gcagtggatc
tgggacagat tacactctca ccatcagcag cctgcagcct 240gaagatgttg caacttatta
ctgtcaaagc aattataacg gtaattatgg tttcggcgga 300gggaccaagg tggagatcaa a
32136107PRTArtificial
SequenceSynthesized 36Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
Ser Val Gly1 5 10 15Asp
Arg Val Thr Ile Asn Cys Gln Ala Ser Gln Asn Ile Tyr Ser Tyr 20
25 30Leu Ser Trp Tyr Gln Gln Lys Pro
Gly Lys Val Pro Lys Arg Leu Ile 35 40
45Tyr Leu Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60Ser Gly Ser Gly Thr Asp Tyr Thr
Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Val Ala Thr Tyr Tyr Cys Gln Ser Asn Tyr Asn
Gly Asn Tyr 85 90 95Gly
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
10537360DNAArtificial SequenceSynthesized 37gaggtgcagc tggtggagtc
tgggggaggc ttggtccagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt
ctccctcaat aactactgga tgagctgggt ccgccaggct 120ccagggaagg ggctggagtg
gatcggaacc attagtagtg gtgcgtatac atggttcgcc 180acctgggcga caggcagatt
caccatctcc agagacaatt ccaagaacac gctgtatctt 240caaatgaaca gcctgagagc
cgaggacacg gctgtgtatt actgtgcgag atattcttct 300actactgatt ggacctactt
taacatctgg ggccagggaa ctctggttac cgtctcttca 36038120PRTArtificial
SequenceSynthesized 38Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Leu Asn Asn Tyr 20
25 30Trp Met Ser Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Ile 35 40
45Gly Thr Ile Ser Ser Gly Ala Tyr Thr Trp Phe Ala Thr Trp Ala Thr
50 55 60Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ser Lys Asn Thr Leu Tyr Leu65 70 75
80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys Ala 85 90 95Arg
Tyr Ser Ser Thr Thr Asp Trp Thr Tyr Phe Asn Ile Trp Gly Gln
100 105 110Gly Thr Leu Val Thr Val Ser
Ser 115 12039324DNAArtificial SequenceSynthesized
39gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc
60atcacttgcc aggccagtca gagcattaat aactacttag cctggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctatagg gcatccactc tggaatctgg ggtcccatca
180aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct
240gatgattttg caacttatta ctgccaaagc tataatggtg ttggtaggac tgctttcggc
300ggagggacca aggtggagat caaa
32440108PRTArtificial SequenceSynthesized 40Asp Ile Gln Met Thr Gln Ser
Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10
15Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile
Asn Asn Tyr 20 25 30Leu Ala
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35
40 45Tyr Arg Ala Ser Thr Leu Glu Ser Gly Val
Pro Ser Arg Phe Ser Gly 50 55 60Ser
Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65
70 75 80Asp Asp Phe Ala Thr Tyr
Tyr Cys Gln Ser Tyr Asn Gly Val Gly Arg 85
90 95Thr Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 10541354DNAArtificial SequenceSynthesized
41gaggtgaagc tggatgagac tggaggaggc ttggtgcaac ctgggaggcc catgaaactc
60tcctgtgttg cctctggatt cacttttagt gactactgga tgaactgggt ccgccagtct
120ccagagaaag gactggagtg ggtagcacaa attagaaaca aaccttataa ttatgaaaca
180tattattcag attctgtgaa aggcagattc accatctcaa gagatgattc caaaagtagt
240gtctacctgc aaatgaacaa cttaagagtt gaagacatgg gtatctatta ctgtacgggt
300tcttactatg gtatggacta ctggggtcaa ggaacctcag tcaccgtctc ctca
35442118PRTArtificial SequenceSynthesized 42Glu Val Lys Leu Asp Glu Thr
Gly Gly Gly Leu Val Gln Pro Gly Arg1 5 10
15Pro Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe
Ser Asp Tyr 20 25 30Trp Met
Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35
40 45Ala Gln Ile Arg Asn Lys Pro Tyr Asn Tyr
Glu Thr Tyr Tyr Ser Asp 50 55 60Ser
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser65
70 75 80Val Tyr Leu Gln Met Asn
Asn Leu Arg Val Glu Asp Met Gly Ile Tyr 85
90 95Tyr Cys Thr Gly Ser Tyr Tyr Gly Met Asp Tyr Trp
Gly Gln Gly Thr 100 105 110Ser
Val Thr Val Ser Ser 11543336DNAArtificial SequenceSynthesized
43gatgtcgtga tgacccaaac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc
60atctcttgca gatctagtca gagccttgta cacagtaatg gaaacaccta tttacgttgg
120tacctgcaga agccaggcca gtctccaaag gtcctgatct acaaagtttc caaccgattt
180tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc
240agcagagtgg aggctgagga tctgggagtt tatttctgct ctcaaagtac acatgttccg
300tggacgttcg gtggaggcac caagctggaa atcaaa
33644112PRTArtificial SequenceSynthesized 44Asp Val Val Met Thr Gln Thr
Pro Leu Ser Leu Pro Val Ser Leu Gly1 5 10
15Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu
Val His Ser 20 25 30Asn Gly
Asn Thr Tyr Leu Arg Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35
40 45Pro Lys Val Leu Ile Tyr Lys Val Ser Asn
Arg Phe Ser Gly Val Pro 50 55 60Asp
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala Glu
Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 85
90 95Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys
Leu Glu Ile Lys 100 105
11045987DNAArtificial SequenceSynthesized 45gctagcacca agggcccatc
ggtcttcccc ctggcaccct cctccaagag cacctctggg 60ggcacagcgg ccctgggctg
cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 120tggaactcag gcgccctgac
cagcggcgtg cacaccttcc cggctgtcct acagtcctca 180ggactctact ccctcagcag
cgtggtgacc gtgccctcca gcagcttggg cacccagacc 240tacatctgca acgtgaatca
caagcccagc aacaccaagg tggacaagag agttgagccc 300aaatcttgtg acaaaactca
cacatgccca ccgtgcccag cacctgaagc cgcgggggca 360ccgtcagtct tcctcttccc
cccaaaaccc aaggacaccc tcatgatctc ccggacccct 420gaggtcacat gcgtggtggt
ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 480tacgtggacg gcgtggaggt
gcataatgcc aagacaaagc cgcgggagga gcagtacaac 540agcacgtacc gtgtggtcag
cgtcctcacc gtcctgcacc aggactggct gaatggcaag 600gagtacaagt gcgcggtctc
caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 660aaagccaaag ggcagccccg
agaaccacag gtgtacaccc tgcccccatc ccgggatgag 720ctgaccaaga accaggtcag
cctgacctgc ctggtcaaag gcttctatcc cagcgacatc 780gccgtggagt gggagagcaa
tgggcagccg gagaacaact acaagaccac gcctcccgtg 840ctggactccg acggctcctt
cttcctctat agcaagctca ccgtggacaa gagcaggtgg 900cagcagggga acgtcttctc
atgctccgtg atgcatgagg ctctgcacaa ccactacacg 960cagaagagcc tctccctgtc
tccgggt 98746329PRTArtificial
SequenceSynthesized 46Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
Ser Ser Lys1 5 10 15Ser
Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20
25 30Phe Pro Glu Pro Val Thr Val Ser
Trp Asn Ser Gly Ala Leu Thr Ser 35 40
45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60Leu Ser Ser Val Val Thr Val Pro
Ser Ser Ser Leu Gly Thr Gln Thr65 70 75
80Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys
Val Asp Lys 85 90 95Arg
Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110Pro Ala Pro Glu Ala Ala Gly
Ala Pro Ser Val Phe Leu Phe Pro Pro 115 120
125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
Cys 130 135 140Val Val Val Asp Val Ser
His Glu Asp Pro Glu Val Lys Phe Asn Trp145 150
155 160Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
Thr Lys Pro Arg Glu 165 170
175Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190His Gln Asp Trp Leu Asn
Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn 195 200
205Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
Lys Gly 210 215 220Gln Pro Arg Glu Pro
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu225 230
235 240Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
Leu Val Lys Gly Phe Tyr 245 250
255Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270Asn Tyr Lys Thr Thr
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275
280 285Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
Gln Gln Gly Asn 290 295 300Val Phe Ser
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr305
310 315 320Gln Lys Ser Leu Ser Leu Ser
Pro Gly 32547321DNAArtificial SequenceSynthesized
47cgtacggtgg ctgcaccatc tgtcttcatc ttcccgccat ctgatgagca gttgaaatct
60ggaactgcct ctgttgtgtg cctgctgaat aacttctatc ccagagaggc caaagtacag
120tggaaggtgg ataacgccct ccaatcgggt aactcccagg agagtgtcac agagcaggac
180agcaaggaca gcacctacag cctcagcagc accctgacgc tgagcaaagc agactacgag
240aaacacaaag tctacgcctg cgaagtcacc catcagggcc tgagctcgcc cgtcacaaag
300agcttcaaca ggggagagtg t
32148107PRTArtificial SequenceSynthesized 48Arg Thr Val Ala Ala Pro Ser
Val Phe Ile Phe Pro Pro Ser Asp Glu1 5 10
15Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
Asn Asn Phe 20 25 30Tyr Pro
Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35
40 45Ser Gly Asn Ser Gln Glu Ser Val Thr Glu
Gln Asp Ser Lys Asp Ser 50 55 60Thr
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu65
70 75 80Lys His Lys Val Tyr Ala
Cys Glu Val Thr His Gln Gly Leu Ser Ser 85
90 95Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105493681DNAArtificial SequenceSynthesized
49gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc
60atcacttgcc agtccagtca gagtgtttat agtaactggt tctcctggta tcagcagaaa
120ccagggaaag cccctaagct cctgatctat tctgcatcca ctctggcatc tggggtccca
180tcaaggttca gcggcagtgg atctgggaca gaattcactc tcaccatcag cagcctgcag
240cctgatgatt ttgcaactta ttactgcgca ggcggttaca atactgttat tgatactttt
300gctttcggcg gagggaccaa ggtggagatc aaaggcggtg gcggtagtgg gggaggcggt
360tctggcggcg gagggtccgg cggtggagga tcagaggtgc agctgttgga gtctggggga
420ggcttggtac agcctggggg gtccctgaga ctctcctgtg cagcctctgg aatcgacttc
480agtaggagat actacatgtg ctgggtccgc caggctccag ggaaggggct ggagtggatc
540gcatgcatat atactggtag ccgcgatact cctcactacg cgagctccgc gaaaggccgg
600ttcaccatct ccagagacaa ttccaagaac acgctgtatc tgcaaatgaa cagcctgaga
660gccgaggaca cggccgtata ttactgtgcg agagaaggta gcctgtgggg ccagggaacc
720ctggtcaccg tctcgagcgg cggtggaggg tccggcggtg gtggatccca gtcggtggag
780gagtctgggg gaggcttggt ccagcctggg gggtccctga gactctcctg tacagcctct
840ggaatcgacc ttaataccta cgacatgatc tgggtccgcc aggctccagg caaggggcta
900gagtgggttg gaatcattac ttatagtggt agtagatact acgcgaactg ggcgaaaggc
960cgattcacca tctccaaaga caataccaag aacacggtgt atctgcaaat gaacagcctg
1020agagctgagg acacggctgt gtattactgt gccagagatt atatgagtgg ttcccacttg
1080tggggccagg gaaccctggt caccgtctct agtgctagca ccaagggccc atcggtcttc
1140cccctggcac cctcctccaa gagcacctct gggggcacag cggccctggg ctgcctggtc
1200aaggactact tccccgaacc ggtgacggtg tcgtggaact caggcgccct gaccagcggc
1260gtgcacacct tcccggctgt cctacagtcc tcaggactct actccctcag cagcgtggtg
1320accgtgccct ccagcagctt gggcacccag acctacatct gcaacgtgaa tcacaagccc
1380agcaacacca aggtggacaa gagagttgag cccaaatctt gtgacaaaac tcacacatgc
1440ccaccgtgcc cagcacctga agccgcgggg gcaccgtcag tcttcctctt ccccccaaaa
1500cccaaggaca ccctcatgat ctcccggacc cctgaggtca catgcgtggt ggtggacgtg
1560agccacgaag accctgaggt caagttcaac tggtacgtgg acggcgtgga ggtgcataat
1620gccaagacaa agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtcctc
1680accgtcctgc accaggactg gctgaatggc aaggagtaca agtgcgcggt ctccaacaaa
1740gccctcccag cccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagaacca
1800caggtgtata ccctgccccc atcccgggat gagctgacca agaaccaggt cagcctgacc
1860tgcctggtca aaggcttcta tcccagcgac atcgccgtgg agtgggagag caatgggcag
1920ccggagaaca actacaagac cacgcctccc gtgctggact ccgacggctc cttcttcctc
1980tatagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt ctcatgctcc
2040gtgatgcatg aggctctgca caaccactac acgcagaaga gcctctccct gtctccgggt
2100ggcggtggag ggtccggcgg tggtggatcc gaggtgcagc tgttggagtc tgggggaggc
2160ttggtacagc ctggggggtc cctgagactc tcctgtgcag cctctggatt caccatcagt
2220cgctaccaca tgacttgggt ccgccaggct ccagggaagg ggctggagtg gatcggacat
2280atttatgtta ataatgatga cacagactac gcgagctccg cgaaaggccg gttcaccatc
2340tccagagaca attccaagaa cacgctgtat ctgcaaatga acagcctgag agccgaggac
2400acggccacct atttctgtgc gagattggat gttggtggtg gtggtgctta tattggggac
2460atctggggcc agggaactct ggttaccgtc tcttcaggcg gtggcggtag tgggggaggc
2520ggttctggcg gcggagggtc cggcggtgga ggatcagaca tccagatgac ccagtctcca
2580tcctccctgt ctgcatctgt aggagacaga gtcaccatca cttgccagtc cagtcagagt
2640gtttataaca acaacgactt agcctggtat cagcagaaac cagggaaagt tcctaagctc
2700ctgatctatt atgcttccac tctggcatct ggggtcccat ctcggttcag tggcagtgga
2760tctgggacag atttcactct caccatcagc agcctgcagc ctgaagatgt tgcaacttat
2820tactgtgcag gcggttatga tacggatggt cttgatacgt ttgctttcgg cggagggacc
2880aaggtggaga tcaaaggcgg tggagggtcc ggcggtggtg gatccgaggt gcagctggtg
2940gagtctgggg gaggcttggt ccagcctggg gggtccctga gactctcctg tgcagcctct
3000ggattcacca tcagtaccaa tgcaatgagc tgggtccgcc aggctccagg gaaggggctg
3060gagtggatcg gagtcattac tggtcgtgat atcacatact acgcgagctg ggcgaaaggc
3120agattcacca tctccagaga caattccaag aacacgctgt atcttcaaat gaacagcctg
3180agagccgagg acacggctgt gtattactgt gcgcgcgacg gtggatcatc tgctattact
3240agtaacaaca tttggggcca aggaactctg gtcaccgttt cttcaggcgg tggcggtagt
3300gggggaggcg gttctggcgg cggagggtcc ggcggtggag gatcagacgt cgtgatgacc
3360cagtctcctt ccaccctgtc tgcatctgta ggagacagag tcaccatcaa ttgccaagcc
3420agtgagagca ttagcagttg gttagcctgg tatcagcaga aaccagggaa agcccctaag
3480ctcctgatct atgaagcatc caaactggca tctggggtcc catcaaggtt cagcggcagt
3540ggatctggga cagagttcac tctcaccatc agcagcctgc agcctgatga ttttgcaact
3600tattactgcc aaggctattt ttattttatt agtcgtactt atgtaaattc tttcggcgga
3660gggaccaagg tggagatcaa a
3681501227PRTArtificial SequenceSynthesized 50Asp Ile Gln Met Thr Gln Ser
Pro Ser Thr Leu Ser Ala Ser Val Gly1 5 10
15Asp Arg Val Thr Ile Thr Cys Gln Ser Ser Gln Ser Val
Tyr Ser Asn 20 25 30Trp Phe
Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu 35
40 45Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly
Val Pro Ser Arg Phe Ser 50 55 60Gly
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln65
70 75 80Pro Asp Asp Phe Ala Thr
Tyr Tyr Cys Ala Gly Gly Tyr Asn Thr Val 85
90 95Ile Asp Thr Phe Ala Phe Gly Gly Gly Thr Lys Val
Glu Ile Lys Gly 100 105 110Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 115
120 125Gly Gly Ser Glu Val Gln Leu Leu Glu
Ser Gly Gly Gly Leu Val Gln 130 135
140Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Asp Phe145
150 155 160Ser Arg Arg Tyr
Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly 165
170 175Leu Glu Trp Ile Ala Cys Ile Tyr Thr Gly
Ser Arg Asp Thr Pro His 180 185
190Tyr Ala Ser Ser Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
195 200 205Lys Asn Thr Leu Tyr Leu Gln
Met Asn Ser Leu Arg Ala Glu Asp Thr 210 215
220Ala Val Tyr Tyr Cys Ala Arg Glu Gly Ser Leu Trp Gly Gln Gly
Thr225 230 235 240Leu Val
Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
245 250 255Gln Ser Val Glu Glu Ser Gly
Gly Gly Leu Val Gln Pro Gly Gly Ser 260 265
270Leu Arg Leu Ser Cys Thr Ala Ser Gly Ile Asp Leu Asn Thr
Tyr Asp 275 280 285Met Ile Trp Val
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly 290
295 300Ile Ile Thr Tyr Ser Gly Ser Arg Tyr Tyr Ala Asn
Trp Ala Lys Gly305 310 315
320Arg Phe Thr Ile Ser Lys Asp Asn Thr Lys Asn Thr Val Tyr Leu Gln
325 330 335Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 340
345 350Asp Tyr Met Ser Gly Ser His Leu Trp Gly Gln Gly
Thr Leu Val Thr 355 360 365Val Ser
Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 370
375 380Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
Leu Gly Cys Leu Val385 390 395
400Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala
405 410 415Leu Thr Ser Gly
Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 420
425 430Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
Ser Ser Ser Leu Gly 435 440 445Thr
Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 450
455 460Val Asp Lys Arg Val Glu Pro Lys Ser Cys
Asp Lys Thr His Thr Cys465 470 475
480Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Ala Pro Ser Val Phe
Leu 485 490 495Phe Pro Pro
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 500
505 510Val Thr Cys Val Val Val Asp Val Ser His
Glu Asp Pro Glu Val Lys 515 520
525Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 530
535 540Pro Arg Glu Glu Gln Tyr Asn Ser
Thr Tyr Arg Val Val Ser Val Leu545 550
555 560Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
Tyr Lys Cys Ala 565 570
575Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
580 585 590Ala Lys Gly Gln Pro Arg
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 595 600
605Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
Val Lys 610 615 620Gly Phe Tyr Pro Ser
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln625 630
635 640Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly 645 650
655Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
660 665 670Gln Gly Asn Val Phe
Ser Cys Ser Val Met His Glu Ala Leu His Asn 675
680 685His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
Gly Gly Gly Gly 690 695 700Ser Gly Gly
Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly705
710 715 720Leu Val Gln Pro Gly Gly Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly 725
730 735Phe Thr Ile Ser Arg Tyr His Met Thr Trp Val Arg
Gln Ala Pro Gly 740 745 750Lys
Gly Leu Glu Trp Ile Gly His Ile Tyr Val Asn Asn Asp Asp Thr 755
760 765Asp Tyr Ala Ser Ser Ala Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn 770 775
780Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp785
790 795 800Thr Ala Thr Tyr
Phe Cys Ala Arg Leu Asp Val Gly Gly Gly Gly Ala 805
810 815Tyr Ile Gly Asp Ile Trp Gly Gln Gly Thr
Leu Val Thr Val Ser Ser 820 825
830Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
835 840 845Gly Gly Gly Ser Asp Ile Gln
Met Thr Gln Ser Pro Ser Ser Leu Ser 850 855
860Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ser Ser Gln
Ser865 870 875 880Val Tyr
Asn Asn Asn Asp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys
885 890 895Val Pro Lys Leu Leu Ile Tyr
Tyr Ala Ser Thr Leu Ala Ser Gly Val 900 905
910Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
Leu Thr 915 920 925Ile Ser Ser Leu
Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Ala Gly 930
935 940Gly Tyr Asp Thr Asp Gly Leu Asp Thr Phe Ala Phe
Gly Gly Gly Thr945 950 955
960Lys Val Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu
965 970 975Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 980
985 990Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile
Ser Thr Asn Ala 995 1000 1005Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 1010
1015 1020Gly Val Ile Thr Gly Arg Asp Ile Thr
Tyr Tyr Ala Ser Trp Ala 1025 1030
1035Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
1040 1045 1050Tyr Leu Gln Met Asn Ser
Leu Arg Ala Glu Asp Thr Ala Val Tyr 1055 1060
1065Tyr Cys Ala Arg Asp Gly Gly Ser Ser Ala Ile Thr Ser Asn
Asn 1070 1075 1080Ile Trp Gly Gln Gly
Thr Leu Val Thr Val Ser Ser Gly Gly Gly 1085 1090
1095Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly 1100 1105 1110Gly Ser Asp Val
Val Met Thr Gln Ser Pro Ser Thr Leu Ser Ala 1115
1120 1125Ser Val Gly Asp Arg Val Thr Ile Asn Cys Gln
Ala Ser Glu Ser 1130 1135 1140Ile Ser
Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 1145
1150 1155Pro Lys Leu Leu Ile Tyr Glu Ala Ser Lys
Leu Ala Ser Gly Val 1160 1165 1170Pro
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu 1175
1180 1185Thr Ile Ser Ser Leu Gln Pro Asp Asp
Phe Ala Thr Tyr Tyr Cys 1190 1195
1200Gln Gly Tyr Phe Tyr Phe Ile Ser Arg Thr Tyr Val Asn Ser Phe
1205 1210 1215Gly Gly Gly Thr Lys Val
Glu Ile Lys 1220 122551651DNAArtificial
SequenceSynthesized 51gcctatgata tgacccagtc tccatcttcc gtgtctgcat
ctgtaggaga cagagtcacc 60atcaagtgtc aggccagtga ggacatttat agcttcttgg
cctggtatca gcagaaacca 120gggaaagccc ctaagctcct gatccattct gcatcctctc
tggcatctgg ggtcccatca 180aggttcagcg gcagtggatc tgggacagat ttcactctca
ccatcagcag cctgcagcct 240gaagattttg caacttacta ttgtcaacag ggttatggta
aaaataatgt tgataatgct 300ttcggcggag ggaccaaggt ggagatcaaa cgtacggtgg
ctgcaccatc tgtcttcatc 360ttcccgccat ctgatgagca gttgaaatct ggaactgcct
ctgttgtgtg cctgctgaat 420aacttctatc ccagagaggc caaagtacag tggaaggtgg
ataacgccct ccaatcgggt 480aactcccagg agagtgtcac agagcaggac agcaaggaca
gcacctacag cctcagcagc 540accctgacgc tgagcaaagc agactacgag aaacacaaag
tctacgcctg cgaagtcacc 600catcagggcc tgagctcgcc cgtcacaaag agcttcaaca
ggggagagtg t 65152217PRTArtificial SequenceSynthesized 52Ala
Tyr Asp Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Lys Cys
Gln Ala Ser Glu Asp Ile Tyr Ser Phe 20 25
30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45His Ser Ala Ser
Ser Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55
60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Gly Lys Asn Asn
85 90 95Val Asp Asn Ala Phe Gly
Gly Gly Thr Lys Val Glu Ile Lys Arg Thr 100
105 110Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser
Asp Glu Gln Leu 115 120 125Lys Ser
Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 130
135 140Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
Ala Leu Gln Ser Gly145 150 155
160Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr
165 170 175Ser Leu Ser Ser
Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His 180
185 190Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
Leu Ser Ser Pro Val 195 200 205Thr
Lys Ser Phe Asn Arg Gly Glu Cys 210 215
User Contributions:
Comment about this patent or add new information about this topic: